A Phase 2 interventional study of SB-497115-GR in Hepatitis C, Chronic, sponsored by GlaxoSmithKline. Completed at 16 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-03-01.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hepatitis C, Chronic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · GlaxoSmithKline.
Among the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline, this one is the 10th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 11th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline is open now. The open studies under Hepatitis C, Chronic, anywhere →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 62 across the 14 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the ability of SB-497115-GR to raise platelet counts in thrombocytopenic patients with hepatitis C virus (HCV) infection (platelet count \<80,000 /μL, suggestive of compensated cirrhosis) to a level desirable to initiate antiviral therapy and to assess the ability of SB-497115-GR to maintain platelet counts at a level sufficient to minimise dose reductions of pegylated interferon (Peg-IFN) and ribavirin (RBV) therapy with the expectation that a lower rate of Peg-IFN dose reduction and omission will translate to a higher rate of sustained viral response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is able to understand and comply with protocol requirements and instructions and is likely to complete the study as planned, as well as provided a written consent.
Female subject with non- [i.e., physiologically incapable of becoming pregnant, who: has had a hysterectomy, or had a bilateral oophorectomy (ovariectomy), or had a bilateral tubal ligation, or is for greater than one year].
Female subject with childbearing potential, has a negative urine or serum pregnancy test at screening and within the 24-hour period prior to the first dose of SB-497115-GR, and completely abstains from intercourse or agree to use two of the following acceptable methods of for 14 days before exposure to SB-497115-GR, throughout the clinical trial, and for 24 weeks after completion or premature discontinuation from the study.
Intrauterine device or intrauterine system that meets the effectiveness criteria as stated in the product label.
Male partner sterilization prior to the female subject's entry into the study, and this male is the sole partner for that subject.
Double-barrier contraception (condom with spermicidal jelly, or diaphragm with spermicide).
Male subject with childbearing potential partner completely abstains from intercourse or agree to use condom and diaphragm with spermicide.
Items Values \<80,000 /μL ≥12.0 g/dL* (ANC) ≥1500 /μL* >50 mL/minute Total \<2.0 mg/dL Albumin >3.0 g/dL >60%
*If the investigators consider the values are sufficient to give Peg-IFN/RBV, then a subject can be enrolled upon consulting the Medical Monitor.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
investigational product for thrombocytopenia
Drug: SB-497115-GR
TPO receptor agonist to increase platelet count
Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1
Participants were assessed for a shift from a baseline platelet count of \<80 Gi/L to a count \>=100 Gi/L during Part 1(up to 9 weeks). Platelet counts were measured by blood draw.
Time frame: From Baseline up to Week 9 in Part 1
Number of Participants Whose Platelet Counts Maintained at >=50 Gi/L During Part 2
Participants were assessed for continuously maintaining platelet counts \>=50 Gi/L during Part 2. Platelet counts were measured by blood draw.
Time frame: From Antiviral Baseline to up to Week 48 in Part 2
Median Platelet Count at the Indicated Time Points in Part 1
Platelet counts were measured by blood draw
Time frame: Baseline, Week1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1
Time in Weeks to Achieve Platelet Count >= 100 Gi/L
Participants were assessed for achieving platelet counts \>=100 Gi/L during Part 1. Platelet counts were measured by blood draw.
Time frame: From Baseline up to Week 9 in Part 1
Median Platelet Count at the Indicated Time Points in Part 2
Platelet counts were measured by blood draw
Time frame: Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Median Platelet Count at the Indicated Time Points During Follow-up Period After Part 2
Platelet counts were measured by blood draw at specified timepoints.
Time frame: Follow-up (FU) Baseline, FU Week 4, FU Week 12 and and FU Week 24 after Part 2
Minimum Platelet Count on Antiviral Therapy
Participants were assessed for platelet counts during antiviral therapy in Part 2. Platelet counts were measured by blood draw.
Time frame: From Antiviral Baseline to up to Week 48 in Part 2
Dose of Eltrombopag That Enabled Initiation of Antiviral Therapy
Participants received eltrombopag at escalating dosages until a platelet count of \>=100 Gi/L was achieved in Part 1. Platelet counts were measured by blood draw.
Time frame: From Baseline up to Week 9 in Part 1
Number of Antiviral Therapy Dose Reductions in Part 2
Number of reductions in Part 2 of either Peg-IFN or RBV. Participants were assigned a score equal to the number of times antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN and/or RBV.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants With the Indicated Levels of Peg-IFN Alpha-2a Therapy Dose Reductions in Part 2
Participants were assigned a score equal to the number of times their Peg-IFN alpha-2a dose of antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants With the Indicated Levels of Peg-IFN Alpha-2b Therapy Dose Reductions in Part 2
Participants were assigned a score equal to the number of times their Peg-IFN alpha-2b dose of antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants With the Indicated Levels of RBV Therapy Dose Reductions in Part 2
Participants were assigned a score equal to the number of times their RBV dose of antiviral therapy was reduced (0=no DRs; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of RBV
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Time to First Dose Reduction of Antiviral Therapy in Part 2
Time to first dose reduction was calucated as the time period from the first dose to the first dose reduction.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants Who Discontinued Antiviral Therapy in Part 2
Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Antviral Therapy was assessed up to 48 weeks in Part 2
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2
Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Peg-IFN alpha-2a therapy was assessed up to 48 weeks in Part 2
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2
Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Peg-IFN alpha-2b therapy was assessed up to 48 weeks in Part 2
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants Achieving Adherence to Antiviral Therapy in Part 2
Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alfa and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2
Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alfa-2a and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2
Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alpha-2b and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants With Sustained Virologic Response (SVR) in Part 2
Participants with SVR were defined as those with undetectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of treatment period Part 2
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) in Part 2
RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA between 4 weeks and 12 weeks after antiviral treatment.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) in Part 2
EVR is defined as a clinically significant reduction from Baseline in HCV RNA (\>=2 log10 decrease in HCV RNA or undetectable HCV RNA) after 12 weeks of antiviral treatment. cEVR, a subset of EVR, is defined exclusively as undetectable HCV RNA after 12 weeks of antiviral treatment.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2
ETR is defined as undetectable HCV RNA at the end of Peg-IFN/RBV treatment.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Mean Serum HCV RNA at the Indicated Time Points In Part 2
The HCV is a small, enveloped, single-stranded, positive-sense RNA virus. Log-Transformed HCV RNA was assessed at Screening, Antiviral Baseline, Part 2 week 4, 12, 24, 36, 48 and at withdrawal.
Time frame: Screening, Antviral baseline; Week 4, 12, 24, 36, 48, Withdrawal in Part 2
Mean Serum HCV RNA at the Indicated Time Points During Follow-up Period After Part 2
The HCV is a small, enveloped, single-stranded, positive-sense RNA virus. Log-Transformed HCV RNA was assessed at FU Baseline, FU Week 12 and FU Week 24 during Follow-up Period after Part 2
Time frame: FU Baseline, FU Week 12 and FU Week 24 after Part 2
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part1
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.
Time frame: From Baseline up to week 9 in Part 1
Number of Participants With Any AE and Any SAE in Part 2
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.
Time frame: From Antiviral Baseline up to Week 48 in Part 2
Number of Participants With Any AE and Any SAE During Follow-up Period After Part 2
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.
Time frame: From FU Baseline up to FU Week 24 after Part 2
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1 With Follow-up Period
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, and FU Week 24
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 2
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
Time frame: Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During Follow-up Period After Part 2
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed.
Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Mean Change From Baseline in Heart Rate at the Indicated Time Points in Part 1 With Follow-up Period
The heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24
Mean Change From Antiviral Baseline in Heart Rate at the Indicated Time Points in Part 2
The heart rate was measured in participants at the indicated time points. Mean change from Antiviral Baseline was calculated as the value at the indicated time points minus the value at Antiviral Baseline.
Time frame: Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Mean Heart Rate at the Indicated Time Points During Follow-up Period After Part 2
The heart rate was measured in participants at the indicated time points.
Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Mean Change From Baseline in Weight at the Indicated Time Points in Part 1 With Follow-up Period
The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24
Mean Change From Baseline in Weight at the Indicated Time Points in Part 2
The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: Baseline; Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Mean Weight at the Indicated Time Points During Follow-up Period After Part 2
The weight of participants was recorded at the indicated time points.
Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 1 With Follow-up Period
The Body temperature of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24
Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 2
The Body temperature of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
Time frame: Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Mean Body Temperature at the Indicated Time Points During Follow-up Period After Part 2
The Body temperature of participants was recorded at the indicated time points..
Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points in Part 1 With Follow-up Periodc
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24
Mean Change From Baseline in BMI at the Indicated Time Points in Part 2
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
Time frame: Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Mean BMI at the Indicated Time Points During Follow-up Period After Part 2
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared.
Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per Division of Acquired Immunodeficiency Syndrome (DAIDS) in Part 1
Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 1. Clinical chemistry parameters included albumin, alkaline phosphatase (ALP), ALT, aspartate amino transferase (AST), total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Time frame: From Baseline up to Week 9
Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS in Part 2
Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 2. Clinical chemistry parameters included albumin, ALP, ALT, AST, total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Time frame: From Antiviral Baseline up to Week 48
Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS During Follow-up Period After Part 2
Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 2. Clinical chemistry parameters included albumin, ALP, ALT, AST, total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Time frame: From FU Week 4 to FU Week 24
Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 1
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 1 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Time frame: From Baseline up to Week 9
Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 2
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 2 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Time frame: From Antiviral Baseline up to Week 48
Number of Participants With the Indicated Shifts From BL in Severity Grades for Hematology Parameters Per DAIDS During Follow-up Period After Part 2
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 2 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
Time frame: From FU Week 4 to FU Week 24
Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part1 With Follow Up Period
Urinalysis parameters included: urine bilirubin (UB), urine occult blood (UOB), urine glucose (UG), urine ketones (UK), pH, urine protein (UP), urine specific gravity (USG) and urine urobilinogen (UU). The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as 1+, (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.
Time frame: Screening, Baseline, Week 1, 2, 3, 4, 7, 8, Withdrawal, FU Week 24
Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part 2
Urinalysis parameters included: UB, UOB, UG, UK, pH, UP, USG and UU. The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as 1+, (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.
Time frame: Antiviral Baseline,Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal
Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points During Follow-up Period After Part 2
Urinalysis parameters included: UB, UOB, UG, UK, pH, UP, USG and UU. The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as 1+, (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.
Time frame: FU Baseline and FU Week 24
Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points
The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal= all ECG parameters within accepted normal ranges. Abnormal= ECG findings outside of normal ranges. CS= ECG with a CS abnormality that meets exclusion criteria. NCS= ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.
Time frame: Screening, Antiviral Baseline, Week 12, 24, 36, 48, Withdrawal
Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) During Follow-up After Part 2
The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal= all ECG parameters within accepted normal ranges. Abnormal= ECG findings outside of normal ranges. CS= ECG with a CS abnormality that meets exclusion criteria. NCS= ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.
Time frame: FU Baseline and FU Week 24
Number of Participants With Abdominal Ultrasound With Doppler at the Indicated Time Points
Abdominal ultrasound with doppler were taken at Baseline, Week 24, Week 48, withdrawal (WD)/completion (comp). Questions were asked to assess masses suspicious for hepatocellular carcinoma (HCC), ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and other clinically significant findings (OCSF).
Time frame: Baseline; Week 24, Week 48, Withdrawal/Completion
Number of Participants With Abdominal Ultrasound With Doppler During Follow-up Period After Part 2
Abdominal ultrasound with doppler were taken during Follow-up Period after Part 2 at FU Week 24. Questions were asked to assess masses suspicious for hepatocellular carcinoma (HCC), ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and other clinically significant findings (OCSF).
Time frame: FU Week 24
Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler in the Study
Abdominal ultrasound with doppler were taken at Baseline, Week 24, Week 48, WD/comp. Questions were asked to assess masses suspicious for HCC, ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and OCSF. Spleen measurements included spleen length and spleen width (breadth).
Time frame: Baseline; Week 24, Week 48, Withdrawal/Completion
Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler During Follow-up Period After Part 2
Abdominal ultrasound with doppler were taken during Follow-up Period after Part 2 at FU Week 24. Questions were asked to assess masses suspicious for HCC, ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and OCSF. Spleen measurements included spleen length and spleen width (breadth).
Time frame: FU Week 24
Participants with chronic hepatitis C (CHC) or compensated liver cirrhosis, who cannot start polyethylene glycol (Peg)-interferon (IFN)/ribavirin (RBV) therapy due to thrombocytopenia (platelet count \<80 giga (10\^9) cells per liter (Gi/L).
| Milestone | Eltrombopag Dose Escalation: Part 1 | Eltrombopag + Antiviral Therapy: Part 2 | Eltrombopag + Antiviral Therapy: Follow-up Period After Part |
|---|---|---|---|
| Started | 45 | 0 | 0 |
| Completed | 41 | 0 | 0 |
| Not completed | 4 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 |
| Withdrew: Protocol-defined stopping criteria | 1 | 0 | 0 |
| Milestone | Eltrombopag Dose Escalation: Part 1 | Eltrombopag + Antiviral Therapy: Part 2 | Eltrombopag + Antiviral Therapy: Follow-up Period After Part |
|---|---|---|---|
| Started | 0 | 41 | 0 |
| Completed | 0 | 31 | 0 |
| Not completed | 0 | 10 | 0 |
| Withdrew: Adverse event | 0 | 7 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Milestone | Eltrombopag Dose Escalation: Part 1 | Eltrombopag + Antiviral Therapy: Part 2 | Eltrombopag + Antiviral Therapy: Follow-up Period After Part |
|---|---|---|---|
| Started | 0 | 0 | 41 |
| Completed | 0 | 0 | 37 |
| Not completed | 0 | 0 | 4 |
| Withdrew: Other | 0 | 0 | 1 |
| Withdrew: Not entered fu period after withdrawal | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
Participants were assessed for a shift from a baseline platelet count of \<80 Gi/L to a count \>=100 Gi/L during Part 1(up to 9 weeks). Platelet counts were measured by blood draw.
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1 | 43 |
Participants were assessed for continuously maintaining platelet counts \>=50 Gi/L during Part 2. Platelet counts were measured by blood draw.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants Whose Platelet Counts Maintained at >=50 Gi/L During Part 2 | 36 |
Platelet counts were measured by blood draw
| 10^9 Cells Per Liter (Gi/L) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Baseline, n=45 | 63.0 (34 to 78) |
| Week 1, n=43 | 74.0 (36 to 108) |
| Week 2, n=36 | 100.0 (43 to 248) |
| Week 3, n=17 | 97.0 (48 to 153) |
| Week 4, n=9 | 104.0 (48 to 137) |
| Week 5, n=4 | 87.0 (49 to 132) |
| Week 6, n=3 | 83.0 (53 to 93) |
| Week 7, n=3 | 97.0 (56 to 103) |
| Week 8, n=2 | 79.0 (63 to 95) |
| Week 9, n=1 | 100.0 (100 to 100) |
| Withdrawal, n=4 | 96 (48 to 115) |
Participants were assessed for achieving platelet counts \>=100 Gi/L during Part 1. Platelet counts were measured by blood draw.
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Within 2 Weeks | 11 |
| Within 4 Weeks | 25 |
| Within 6 Weeks | 5 |
| Within 8 Weeks | 1 |
| Within 9 Weeks | 0 |
| Greater than 9 Weeks | 1 |
Platelet counts were measured by blood draw
| Gi/L | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Antiviral Baseline, n=41 | 114.0 (100 to 248) |
| Week 1, n=40 | 106.5 (50 to 431) |
| Week 2, n=40 | 118.0 (58 to 309) |
| Week 4, n=37 | 89.0 (43 to 126) |
| Week 6, n=36 | 86.0 (38 to 130) |
| Week 8, n=36 | 79.5 (53 to 130) |
| Week 12, n=36 | 80.5 (55 to 161) |
| Week 16, n=36 | 79.5 (49 to 128) |
| Week 20, n=36 | 75.5 (54 to 119) |
| Week 24, n=36 | 76.5 (29 to 128) |
| Week 28, n=34 | 75.0 (49 to 128) |
| Week 32, n=34 | 73.0 (30 to 161) |
| Week 36, n=34 | 76.0 (43 to 148) |
| Week 40, n=33 | 80.0 (48 to 135) |
| Week 44, n=31 | 79.0 (37 to 172) |
| Week 48, n=31 | 82.0 (49 to 170) |
| Withdrawal, n=10 | 102.0 (54 to 207) |
Platelet counts were measured by blood draw at specified timepoints.
| Gi/L | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Baseline, n=34 | 86.5 (36 to 184) |
| FU Week 4, n=34 | 82.5 (43 to 645) |
| FU Week 12, n=34 | 70.0 (37 to 154) |
| FU Week 24, n=31 | 63.0 (41 to 145) |
Participants were assessed for platelet counts during antiviral therapy in Part 2. Platelet counts were measured by blood draw.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| <25 Gi/L | 0 |
| >=25 to <50 Gi/L | 5 |
| >=50 to <100 Gi/L | 34 |
| >=100 to <150 Gi/L | 2 |
| >=150 to <200 Gi/L | 0 |
| >=200 to <400 Gi/L | 0 |
| >= 400 Gi/L | 0 |
Participants received eltrombopag at escalating dosages until a platelet count of \>=100 Gi/L was achieved in Part 1. Platelet counts were measured by blood draw.
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Eltrombopag 0 mg | 1 |
| Eltrombopag 12.5 mg | 25 |
| Eltrombopag 25 mg | 13 |
| Eltrombopag 37.5 mg | 0 |
| Eltrombopag 50 mg | 2 |
| Did not initiate antiviral therapy | 4 |
Number of reductions in Part 2 of either Peg-IFN or RBV. Participants were assigned a score equal to the number of times antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN and/or RBV.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| 0 DR | 8 |
| 1 DR | 9 |
| 2 DR | 10 |
| 3 DR | 3 |
| 4 DR | 2 |
| 5 DR | 1 |
| 7 DR | 3 |
| 8 DR | 1 |
| 10 DR | 2 |
Participants were assigned a score equal to the number of times their Peg-IFN alpha-2a dose of antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| 0 DR | 4 |
| 1 DR | 6 |
| 2 DR | 4 |
| 3 DR | 1 |
| >3 DR | 1 |
Participants were assigned a score equal to the number of times their Peg-IFN alpha-2b dose of antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| 0 DR | 16 |
| 1 DR | 2 |
| 2 DR | 4 |
| 3 DR | 0 |
| >3 DR | 3 |
Participants were assigned a score equal to the number of times their RBV dose of antiviral therapy was reduced (0=no DRs; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of RBV
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| 0 DR | 14 |
| 1 DR | 12 |
| 2 DR | 9 |
| 3 DR | 3 |
| >3 DR | 3 |
Time to first dose reduction was calucated as the time period from the first dose to the first dose reduction.
| weeks | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Peg-IFN alfa-2a dose reduction, n=12 | 9.44 ± 12.556 |
| Peg-IFN alfa-2b dose reduction, n=9 | 6.22 ± 6.944 |
| RBV dose reduction, n=27 | 9.16 ± 6.611 |
Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Antviral Therapy was assessed up to 48 weeks in Part 2
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants Who Discontinued Antiviral Therapy in Part 2 | 8 |
Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Peg-IFN alpha-2a therapy was assessed up to 48 weeks in Part 2
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2 | 1 |
Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Peg-IFN alpha-2b therapy was assessed up to 48 weeks in Part 2
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2 | 7 |
Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alfa and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants Achieving Adherence to Antiviral Therapy in Part 2 | 32 |
Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alfa-2a and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2 | 14 |
Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alpha-2b and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2 | 18 |
Participants with SVR were defined as those with undetectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of treatment period Part 2
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants With Sustained Virologic Response (SVR) in Part 2 | 9 |
RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA between 4 weeks and 12 weeks after antiviral treatment.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| RVR | 6 |
| eRVR | 5 |
EVR is defined as a clinically significant reduction from Baseline in HCV RNA (\>=2 log10 decrease in HCV RNA or undetectable HCV RNA) after 12 weeks of antiviral treatment. cEVR, a subset of EVR, is defined exclusively as undetectable HCV RNA after 12 weeks of antiviral treatment.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| EVR | 28 |
| cEVR | 18 |
ETR is defined as undetectable HCV RNA at the end of Peg-IFN/RBV treatment.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2 | 19 |
The HCV is a small, enveloped, single-stranded, positive-sense RNA virus. Log-Transformed HCV RNA was assessed at Screening, Antiviral Baseline, Part 2 week 4, 12, 24, 36, 48 and at withdrawal.
| Log international unit per milliliter | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Screening, n=41 | 6.41 ± 0.726 |
| Antiviral Baseline, n=41 | 6.37 ± 0.767 |
| Week 4, n=37 | 3.77 ± 1.741 |
| Week 12, n=36 | 2.52 ± 1.734 |
| Week 24, n=36 | 2.46 ± 1.876 |
| Week 36, n=34 | 2.69 ± 2.177 |
| Week 48, n=31 | 2.63 ± 2.275 |
| Withdrawal, n=10 | 3.87 ± 2.275 |
The HCV is a small, enveloped, single-stranded, positive-sense RNA virus. Log-Transformed HCV RNA was assessed at FU Baseline, FU Week 12 and FU Week 24 during Follow-up Period after Part 2
| Log international unit per milliliter | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Baseline, n=34 | 3.10 ± 2.422 |
| FU Week 12, n=34 | 5.04 ± 2.551 |
| FU Week 24, n=31 | 4.82 ± 2.436 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Any AE | 13 |
| Any SAE | 0 |
| Fatal AE | 0 |
| Drug-related AE | 4 |
| AE leading to withdrawal | 0 |
| SAE leading to withdrawal | 0 |
| On-going AE at the endo of study/withdrawal | 1 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Any AE | 41 |
| Any SAE | 3 |
| Fatal AE | 0 |
| Drug-related AE | 41 |
| AE leading to withdrawal | 9 |
| SAE leading to withdrawal | 3 |
| On-going AE at the end of study/withdrawal | 34 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.
| Participants | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| Any AE | 25 |
| Any SAE | 4 |
| Fatal AE | 0 |
| Drug-related AE | 6 |
| AE leading to withdrawal | 0 |
| SAE leading to withdrawal | 0 |
| On-going AE at the end of study/withdrawal | 16 |
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
| Millimeter of mercury (mmHg) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| SBP, Week 1, n=38 | 0.9 ± 9.86 |
| SBP, Week 2, n=30 | -1.7 ± 12.42 |
| SBP, Week 3, n=11 | 2.8 ± 11.07 |
| SBP, Week 4, n=6 | -2.8 ± 9.79 |
| SBP, Week 5, n=3 | -1.0 ± 9.54 |
| SBP, Week 6, n=3 | -4.0 ± 3.00 |
| SBP, Week 7, n=3 | -1.3 ± 5.69 |
| SBP, Week 8, n=2 | 12.0 ± 15.56 |
| SBP, Week 9, n=1 | 3.0 ± NA |
| SBP, Withdrawal, n=4 | 13.5 ± 13.96 |
| SBP, Follow Up, week 4, n=3 | -1.0 ± 8.54 |
| SBP, Follow Up, week 12, n=3 | 9.0 ± 8.89 |
| SBP, Follow Up, week 24, n=3 | 2.7 ± 10.07 |
| DBP, Week 1, n=38 | -0.5 ± 8.81 |
| DBP, Week 2, n=30 | -2.1 ± 8.04 |
| DBP, Week 3, n=11 | -1.6 ± 7.98 |
| DBP, Week 4, n=6 | -1.7 ± 8.04 |
| DBP, Week 5, n=3 | -7.3 ± 9.87 |
| DBP, Week 6, n=3 | -3.3 ± 7.64 |
| DBP, Week 7, n=3 | -9.0 ± 7.00 |
| DBP, Week 8, n=2 | 6.0 ± 14.14 |
| DBP, Week 9, n=1 | -10.0 ± NA |
| DBP, Withdrawal, n=4 | 5.8 ± 12.09 |
| DBP, FU Week 4, n=3 | 0.3 ± 5.51 |
| DBP, FU Week 12, n=3 | 4.0 ± 10.39 |
| DBP, FU Week 24, n=3 | -0.3 ± 1.53 |
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
| mmHg | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| SBP, Antiviral Baseline, n=40 | 0.2 ± 13.99 |
| SBP, Week 1, n=40 | -5.9 ± 10.37 |
| SBP, Week 2, n=40 | -8.7 ± 13.35 |
| SBP, Week 4, n=37 | -5.2 ± 13.69 |
| SBP, Week 6, n=36 | -3.9 ± 13.09 |
| SBP, Week 8, n=36 | -6.0 ± 14.53 |
| SBP, Week 12, n=36 | -5.7 ± 13.08 |
| SBP, Week 16, n=36 | -5.5 ± 16.52 |
| SBP, Week 20, n=36 | -4.4 ± 15.18 |
| SBP, Week 24, n=36 | -2.1 ± 15.70 |
| SBP, Week 28, n=34 | -6.3 ± 15.76 |
| SBP, Week 32, n=34 | -5.2 ± 17.60 |
| SBP, Week 36, n=34 | -5.6 ± 15.36 |
| SBP, Week 40, n=33 | -5.1 ± 13.47 |
| SBP, Week 44, n=31 | -4.6 ± 16.60 |
| SBP, Week 48, n=31 | -2.9 ± 12.37 |
| SBP, withdrawal, n=10 | 0.5 ± 17.26 |
| DBP, Antiviral Baseline, n=40 | -0.4 ± 6.35 |
| DBP, Week 1, n=40 | -3.5 ± 9.28 |
| DBP, Week 2, n=40 | -4.0 ± 9.59 |
| DBP, Week 4, n=37 | -3.5 ± 9.81 |
| DBP, Week 6, n=36 | -3.9 ± 9.16 |
| DBP, Week 8, n=36 | -6.0 ± 9.62 |
| DBP, Week 12, n=36 | -5.9 ± 10.07 |
| DBP, Week 16, n=36 | -4.7 ± 9.94 |
| DBP, Week 20, n=36 | -5.7 ± 11.17 |
| DBP, Week 24, n=36 | -4.5 ± 12.34 |
| DBP, Week 28, n=34 | -7.9 ± 11.48 |
| DBP, Week 32, n=34 | -7.1 ± 11.97 |
| DBP, Week 36, n=34 | -5.4 ± 9.96 |
| DBP, Week 40, n=33 | -6.8 ± 9.69 |
| DBP, Week 44, n=31 | -5.8 ± 12.18 |
| DBP, Week 48, n=31 | -3.8 ± 8.36 |
| DBP, withdrawal, n=10 | -2.4 ± 8.24 |
Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed.
| mmHg | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| SBP, FU Baseline, n=40 | 126.5 ± 11.30 |
| SBP, FU Week 4, n=40 | 125.4 ± 11.74 |
| SBP, Week 12, n=40 | 126.7 ± 10.86 |
| SBP, Week 24, n=37 | 128.4 ± 12.68 |
| DBP, FU Baseline, n=40 | 73.8 ± 8.85 |
| DBP, FU Week 4, n=40 | 74.3 ± 8.91 |
| DBP, FU Week 12, n=40 | 76.2 ± 9.40 |
| DBP, FU Week 24, n=37 | 75.7 ± 9.48 |
The heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
| Beats per minute (bpm) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Week 1, n=38 | 0.1 ± 7.07 |
| Week 2, n=30 | -0.1 ± 7.42 |
| Week 3, n=11 | 0.1 ± 4.50 |
| Week 4, n=6 | 2.8 ± 4.07 |
| Week 5, n=3 | 0.3 ± 7.37 |
| Week 6, n=3 | 2.0 ± 5.29 |
| Week 7, n=3 | 3.0 ± 7.00 |
| Week 8, n=2 | -1.0 ± 5.66 |
| Week 9, n=1 | -4.0 ± NA |
| Withdrawal, n=4 | 2.8 ± 8.30 |
| FU Week 4, n=3 | 0.7 ± 12.66 |
| FU Week 12, n=3 | 3.7 ± 9.07 |
| FU Week 24, n=3 | 2.0 ± 9.54 |
The heart rate was measured in participants at the indicated time points. Mean change from Antiviral Baseline was calculated as the value at the indicated time points minus the value at Antiviral Baseline.
| bpm | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Antiviral Baseline, n=40 | 0.4 ± 7.56 |
| Week 1, n=40 | -3.5 ± 9.51 |
| Week 2, n=40 | 1.0 ± 9.57 |
| Week 4, n=37 | 3.9 ± 9.29 |
| Week 6, n=36 | 5.9 ± 9.78 |
| Week 8, n=36 | 4.7 ± 10.60 |
| Week 12, n=36 | 5.8 ± 10.34 |
| Week 16, n=36 | 6.2 ± 9.91 |
| Week 20, n=36 | 4.5 ± 10.54 |
| Week 24, n=36 | 4.5 ± 9.79 |
| Week 28, n=34 | 5.6 ± 9.85 |
| Week 32, n=34 | 3.6 ± 8.80 |
| Week 36, n=34 | 4.7 ± 9.07 |
| Week 40, n=33 | 5.2 ± 8.20 |
| Week 44, n=31 | 5.2 ± 7.11 |
| Week 48, n=31 | 3.6 ± 7.18 |
| Withdrawal, n=10 | 5.1 ± 11.86 |
The heart rate was measured in participants at the indicated time points.
| bpm | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Baseline, n=40 | 78.3 ± 8.77 |
| FU Week 4, n=40 | 79.5 ± 9.38 |
| FU Week 12, n=40 | 74.0 ± 8.64 |
| FU Week 24, n=37 | 74.6 ± 9.58 |
The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
| Kilogram (kg) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Week 1, n=38 | 0.09 ± 0.807 |
| Week 2, n=30 | 0.05 ± 1.239 |
| Week 3, n=11 | 0.75 ± 1.196 |
| Week 4, n=6 | 1.15 ± 0.931 |
| Week 5, n=3 | 1.00 ± 1.400 |
| Week 6, n=3 | 1.03 ± 0.723 |
| Week 7, n=3 | 0.57 ± 1.159 |
| Week 8, n=2 | 0.15 ± 1.909 |
| Week 9, n=1 | 0.20 ± NA |
| Withdrawal, n=4 | 0.30 ± 1.519 |
| FU Week 4, n=3 | 0.90 ± 1.212 |
| FU Week 12, n=3 | 0.93 ± 3.009 |
| FU Week 24, n=3 | 1.17 ± 2.894 |
The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
| kg | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Antivital Baseline, n=40 | 0.04 ± 1.336 |
| Week 1, n=40 | -0.95 ± 1.131 |
| Week 2, n=40 | -1.14 ± 1.314 |
| Week 4, n=37 | -1.04 ± 1.060 |
| Week 6, n=36 | -1.05 ± 1.344 |
| Week 8, n=36 | -1.28 ± 1.581 |
| Week 12, n=36 | -1.73 ± 1.887 |
| Week 16, n=36 | -2.13 ± 2.175 |
| Week 20, n=36 | -2.49 ± 2.265 |
| Week 24, n=36 | -3.11 ± 2.488 |
| Week 28, n=34 | -3.00 ± 3.104 |
| Week 32, n=34 | -3.16 ± 3.100 |
| Week 36, n=34 | -3.43 ± 3.188 |
| Week 40, n=33 | -3.61 ± 3.000 |
| Week 44, n=31 | -3.39 ± 3.018 |
| Week 48, n=31 | -3.76 ± 2.950 |
| Withdrawal, n=10 | -3.04 ± 3.584 |
The weight of participants was recorded at the indicated time points.
| kg | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Baseline, n=40 | 55.77 ± 11.403 |
| FU Week 4, n=40 | 56.37 ± 11.627 |
| FU Week 12, n=40 | 57.05 ± 11.841 |
| FU Week 24, n=37 | 57.84 ± 12.478 |
The Body temperature of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.
| Degrees centigrade | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Week 1, n=38 | -0.04 ± 0.439 |
| Week 2, n=30 | 0.03 ± 0.445 |
| Week 3, n=11 | 0.06 ± 0.284 |
| Week 4, n=6 | 0.07 ± 0.367 |
| Week 5, n=3 | -0.07 ± 0.153 |
| Week 6, n=3 | -0.10 ± 0.173 |
| Week 7, n=3 | -0.40 ± 0.100 |
| Week 8, n=2 | -0.50 ± 0.141 |
| Week 9, n=1 | -1.10 ± NA |
| Withdrawal, n=4 | -0.18 ± 0.171 |
| FU Week 4, n=3 | 0.07 ± 0.153 |
| FU Week 12, n=3 | -0.23 ± 0.493 |
| FU Week 24, n=3 | -0.17 ± 0.306 |
The Body temperature of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
| Degrees centigrade | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Antiviral Baseline, n=41 | 0.08 ± 0.662 |
| Week 1, n=40 | 0.09 ± 0.398 |
| Week 2, n=40 | 0.17 ± 0.459 |
| Week 4, n=37 | 0.16 ± 0.439 |
| Week 6, n=36 | 0.19 ± 0.499 |
| Week 8, n=36 | 0.22 ± 0.426 |
| Week 12, n=36 | 0.28 ± 0.440 |
| Week 16, n=36 | 0.22 ± 0.392 |
| Week 20, n=36 | 0.20 ± 0.386 |
| Week 24, n=36 | 0.26 ± 0.422 |
| Week 28, n=34 | 0.27 ± 0.424 |
| Week 32, n=34 | 0.21 ± 0.435 |
| Week 36, n=34 | 0.22 ± 0.462 |
| Week 40, n=33 | 0.26 ± 0.374 |
| Week 44, n=31 | 0.20 ± 0.492 |
| Week 48, n=31 | 0.15 ± 0.498 |
| Withdrawal, n=10 | 0.38 ± 0.724 |
The Body temperature of participants was recorded at the indicated time points..
| Degrees centigrade | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Baseline, n=40 | 36.44 ± 0.417 |
| FU Week 4, n=40 | 36.37 ± 0.360 |
| FU Week 12, n=40 | 36.29 ± 0.350 |
| FU Week 24, n=37 | 36.90 ± 0.377 |
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
| kilogram per meters squared (kg/m^2) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Week 1, n=38 | 0.03 ± 0.302 |
| Week 2, n=30 | 0.02 ± 0.457 |
| Week 3, n=11 | 0.26 ± 0.415 |
| Week 4, n=6 | 0.39 ± 0.325 |
| Week 5, n=3 | 0.36 ± 0.504 |
| Week 6, n=3 | 0.36 ± 0.248 |
| Week 7, n=3 | 0.20 ± 0.417 |
| Week 8, n=2 | 0.04 ± 0.704 |
| Week 9, n=1 | 0.08 ± NA |
| Withdrawal, n=4 | 0.09 ± 0.572 |
| FU, Week 4, n=3 | 0.34 ± 0.432 |
| FU, Week 12, n=3 | 0.36 ± 1.084 |
| FU, Week 24, n=3 | 0.41 ± 1.042 |
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline
| kg/m^2 | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Antiviral Baseline, n=40 | 0.01 ± 0.476 |
| Week 1, n=40 | -0.37 ± 0.408 |
| Week 2, n=40 | -0.44 ± 0.495 |
| Week 4, n=37 | -0.41 ± 0.424 |
| Week 6, n=36 | -0.42 ± 0.534 |
| Week 8, n=36 | -0.51 ± 0.624 |
| Week 12, n=36 | -0.70 ± 0.723 |
| Week 16, n=36 | -0.86 ± 0.844 |
| Week 20, n=36 | -1.01 ± 0.891 |
| Week 24, n=36 | -1.25 ± 0.965 |
| Week 28, n=34 | -1.21 ± 1.212 |
| Week 32, n=34 | -1.28 ± 1.228 |
| Week 36, n=34 | -1.38 ± 1.264 |
| Week 40, n=33 | -1.45 ± 1.200 |
| Week 44, n=31 | -1.36 ± 1.174 |
| Week 48, n=31 | -1.50 ± 1.146 |
| Withdrawal, n=10 | -1.23 ± 1.529 |
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared.
| kilogram per meters squared (kg/m^2) | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Baseline, n=40 | 21.89 ± 3.486 |
| FU Week 4, n=40 | 22.11 ± 3.474 |
| FU Week 12, n=40 | 22.37 ± 3.531 |
| FU Week 24, n=37 | 22.54 ± 3.521 |
Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 1. Clinical chemistry parameters included albumin, alkaline phosphatase (ALP), ALT, aspartate amino transferase (AST), total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Albumin: Any Grade Increase | 5 |
| Albumin: Increase to G1 | 5 |
| Albumin: Increase to G2 | 0 |
| Albumin: Increase to G3 | 0 |
| Albumin: Increase to G4 | 0 |
| ALP: Any Grade Increase | 4 |
| ALP: Increase to G1 | 2 |
| ALP: Increase to G2 | 2 |
| ALP: Increase to G3 | 0 |
| ALP: Increase to G4 | 0 |
| ALT: Any Grade Increase | 5 |
| ALT: Increase to G1 | 1 |
| ALT: Increase to G2 | 2 |
| ALT: Increase to G3 | 2 |
| ALT: Increase to G4 | 0 |
| AST:Any Grade Increase | 9 |
| AST:Increase to G1 | 2 |
| AST:Increase to G2 | 5 |
| AST:Increase to G3 | 2 |
| AST:Increase to G4 | 0 |
| Total Bilirubin:Any Grade Increase | 8 |
| Total Bilirubin:Increase to G1 | 6 |
| Total Bilirubin:Increase to G2 | 2 |
| Total Bilirubin:Increase to G3 | 0 |
| Total Bilirubin:Increase to G4 | 0 |
| Calcium:Any Grade Increase | 5 |
| Calcium:Increase to G1 | 5 |
| Calcium:Increase to G2 | 0 |
| Calcium:Increase to G3 | 0 |
| Calcium:Increase to G4 | 0 |
| Creatinine:Any Grade Increase | 1 |
| Creatinine:Increase to G1 | 1 |
| Creatinine:Increase to G2 | 0 |
| Creatinine:Increase to G3 | 0 |
| Creatinine:Increase to G4 | 0 |
| Potassium:Any Grade Increase | 3 |
| Potassium:Increase to G1 | 3 |
| Potassium:Increase to G2 | 0 |
| Potassium:Increase to G3 | 0 |
| Potassium:Increase to G4 | 0 |
| Sodium:Any Grade Increase | 2 |
| Sodium:Increase to G1 | 2 |
| Sodium:Increase to G2 | 0 |
| Sodium:Increase to G3 | 0 |
| Sodium:Increase to G4 | 0 |
| Uric Acid:Any Grade Increase | 6 |
| Uric acid:Increase to G1 | 5 |
| Uric acid:Increase to G2 | 1 |
| Uric acid:Increase to G3 | 0 |
| Uric acid:Increase to G4 | 0 |
Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 2. Clinical chemistry parameters included albumin, ALP, ALT, AST, total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Albumin:Any Grade Increase | 18 |
| Albumin:Increase to G1 | 15 |
| Albumin:Increase to G2 | 3 |
| Albumin:Increase to G3 | 0 |
| Albumin:Increase to G4 | 0 |
| ALP:Any Grade Increase | 3 |
| ALP:Increase to G1 | 3 |
| ALP:Increase to G2 | 0 |
| ALP:Increase to G3 | 0 |
| ALP:Increase to G4 | 0 |
| ALT:Any Grade Increase | 14 |
| ALT:Increase to G1 | 1 |
| ALT:Increase to G2 | 6 |
| ALT:Increase to G3 | 6 |
| ALT:Increase to G4 | 1 |
| AST:Any Grade Increase | 22 |
| AST:Increase to G1 | 4 |
| AST:Increase to G2 | 11 |
| AST:Increase to G3 | 6 |
| AST:Increase to G4 | 1 |
| Total Bilirubin:Any Grade Increase | 20 |
| Total Bilirubin:Increase to G1 | 7 |
| Total Bilirubin:Increase to G2 | 9 |
| Total Bilirubin:Increase to G3 | 3 |
| Total Bilirubin:Increase to G4 | 1 |
| Calcium:Any Grade Increase | 31 |
| Calcium:Increase to G1 | 25 |
| Calcium:Increase to G2 | 6 |
| Calcium:Increase to G3 | 0 |
| Calcium:Increase to G4 | 0 |
| Creatinine:Any Grade Increase | 3 |
| Creatinine:Increase to G1 | 2 |
| Creatinine:Increase to G2 | 1 |
| Creatinine:Increase to G3 | 0 |
| Creatinine:Increase to G4 | 0 |
| Potassium:Any Grade Increase | 8 |
| Potassium:Increase to G1 | 8 |
| Potassium:Increase to G2 | 0 |
| Potassium:Increase to G3 | 0 |
| Potassium:Increase to G4 | 0 |
| Sodium:Any Grade Increase | 7 |
| Sodium:Increase to G1 | 7 |
| Sodium:Increase to G2 | 0 |
| Sodium:Increase to G3 | 0 |
| Sodium:Increase to G4 | 0 |
| Uric acid:Any Grade Increase | 13 |
| Uric acid:Increase to G1 | 9 |
| Uric acid:Increase to G2 | 4 |
| Uric acid:Increase to G3 | 0 |
| Uric acid:Increase to G4 | 0 |
Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 2. Clinical chemistry parameters included albumin, ALP, ALT, AST, total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
| Participants | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| Albumin:Any Grade Increase | 3 |
| Albumin:Increase to G1 | 2 |
| Albumin:Increase to G2 | 1 |
| Albumin:Increase to G3 | 0 |
| Albumin:Increase to G4 | 0 |
| ALP:Any Grade Increase | 5 |
| ALP:Increase to G1 | 4 |
| ALP:Increase to G2 | 1 |
| ALP:Increase to G3 | 0 |
| ALP:Increase to G4 | 0 |
| ALT:Any Grade Increase | 9 |
| ALT:Increase to G1 | 4 |
| ALT:Increase to G2 | 4 |
| ALT:Increase to G3 | 0 |
| ALT:Increase to G4 | 1 |
| AST:Any Grade Increase | 10 |
| AST:Increase to G1 | 3 |
| AST:Increase to G2 | 6 |
| AST:Increase to G3 | 0 |
| AST:Increase to G4 | 1 |
| Total Bilirubin:Any Grade Increase | 4 |
| Total Bilirubin:Increase to G1 | 2 |
| Total Bilirubin:Increase to G2 | 2 |
| Total Bilirubin:Increase to G3 | 0 |
| Total Bilirubin:Increase to G4 | 0 |
| Calcium:Any Grade Increase | 2 |
| Calcium:Increase to G1 | 2 |
| Calcium:Increase to G2 | 0 |
| Calcium:Increase to G3 | 0 |
| Calcium:Increase to G4 | 0 |
| Calcium serum high: Any Grade Increase | 0 |
| Calcium, serum high: Increase to G1 | 0 |
| Calcium, serum high: Increase to G2 | 0 |
| Calcium, serum high: Increase to G3 | 0 |
| Calcium, serum high: Increase to G4 | 0 |
| Calcium serum low: Any Grade Increase | 2 |
| Calcium, serum low: Increase to G1 | 2 |
| Calcium, serum low: Increase to G2 | 0 |
| Calcium, serum low: Increase to G3 | 0 |
| Calcium, serum low: Increase to G4 | 0 |
| Creatinine: Any Grade Increase | 1 |
| Creatinine: Increase to G1 | 1 |
| Creatinine: Increase to G2 | 0 |
| Creatinine: Increase to G3 | 0 |
| Creatinine: Increase to G4 | 0 |
| Potassium:Any Grade Increase | 3 |
| Potassium:Increase to G1 | 3 |
| Potassium:Increase to G2 | 0 |
| Potassium:Increase to G3 | 0 |
| Potassium:Increase to G4 | 0 |
| Potassium, serum high:Any Grade Increase | 0 |
| Potassium, serum high:Increase to G1 | 0 |
| Potassium, serum high:Increase to G2 | 0 |
| Potassium, serum high:Increase to G3 | 0 |
| Potassium, serum high:Increase to G4 | 0 |
| Potassium, serum low:Any Grade Increase | 3 |
| Potassium, serum low:Increase to G1 | 3 |
| Potassium, serum low:Increase to G2 | 0 |
| Potassium, serum low:Increase to G3 | 0 |
| Potassium, serum low:Increase to G4 | 0 |
| Sodium:Any Grade Increase | 1 |
| Sodium:Increase to G1 | 1 |
| Sodium:Increase to G2 | 0 |
| Sodium:Increase to G3 | 0 |
| Sodium:Increase to G4 | 0 |
| Sodium, serum high:Any Grade Increase | 1 |
| Sodium, serum high:Increase to G1 | 1 |
| Sodium, serum high:Increase to G2 | 0 |
| Sodium, serum high:Increase to G3 | 0 |
| Sodium, serum high:Increase to G4 | 0 |
| Sodium, serum low:Any Grade Increase | 0 |
| Sodium, serum low:Increase to G1 | 0 |
| Sodium, serum low:Increase to G2 | 0 |
| Sodium, serum low:Increase to G3 | 0 |
| Sodium, serum low:Increase to G4 | 0 |
| Uric acid:Any Grade Increase | 2 |
| Uric acid:Increase to G1 | 2 |
| Uric acid:Increase to G2 | 0 |
| Uric acid:Increase to G3 | 0 |
| Uric acid:Increase to G4 | 0 |
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 1 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Hemoglobin:Any Grade Increase | 1 |
| Hemoglobin:Increase to G1 | 1 |
| Hemoglobin:Increase to G2 | 0 |
| Hemoglobin:Increase to G3 | 0 |
| Hemoglobin:Increase to G4 | 0 |
| Lymphocytes:Any Grade Increase | 4 |
| Lymphocytes:Increase to G1 | 1 |
| Lymphocytes:Increase to G2 | 0 |
| Lymphocytes:Increase to G3 | 3 |
| Lymphocytes:Increase to G4 | 0 |
| Total Neutrophils:Any Grade Increase | 8 |
| Total Neutrophils:Increase to G1 | 6 |
| Total Neutrophils:Increase to G2 | 2 |
| Total Neutrophils:Increase to G3 | 0 |
| Total Neutrophils:Increase to G4 | 0 |
| Platelet count:Any Grade Increase | 0 |
| Platelet count:Increase to G1 | 0 |
| Platelet count:Increase to G2 | 0 |
| Platelet count:Increase to G3 | 0 |
| Platelet count:Increase to G4 | 0 |
| White Blood Cell count:Any Grade Increase | 7 |
| White Blood Cell count:Increase to G1 | 7 |
| White Blood Cell count:Increase to G2 | 0 |
| White Blood Cell count:Increase to G3 | 0 |
| White Blood Cell count:Increase to G4 | 0 |
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 2 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Hemoglobin:Any Grade Increase | 38 |
| Hemoglobin:Increase to G1 | 3 |
| Hemoglobin:Increase to G2 | 11 |
| Hemoglobin:Increase to G3 | 24 |
| Hemoglobin:Increase to G4 | 0 |
| Lymphocytes:Any Grade Increase | 26 |
| Lymphocytes:Increase to G1 | 0 |
| Lymphocytes:Increase to G2 | 6 |
| Lymphocytes:Increase to G3 | 12 |
| Lymphocytes:Increase to G4 | 8 |
| Total Neutrophils:Any Grade Increase | 38 |
| Total Neutrophils:Increase to G1 | 8 |
| Total Neutrophils:Increase to G2 | 10 |
| Total Neutrophils:Increase to G3 | 16 |
| Total Neutrophils:Increase to G4 | 4 |
| Platelet count:Any Grade Increase | 5 |
| Platelet count:Increase to G1 | 0 |
| Platelet count:Increase to G2 | 0 |
| Platelet count:Increase to G3 | 5 |
| Platelet count:Increase to G4 | 0 |
| White Blood Cell count:Any Grade Increase | 38 |
| White Blood Cell count:Increase to G1 | 10 |
| White Blood Cell count:Increase to G2 | 18 |
| White Blood Cell count:Increase to G3 | 9 |
| White Blood Cell count:Increase to G4 | 1 |
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 2 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
| Participants | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| Hemoglobin:Any Grade Increase | 2 |
| Hemoglobin:Increase to G1 | 2 |
| Hemoglobin:Increase to G2 | 0 |
| Hemoglobin:Increase to G3 | 0 |
| Hemoglobin:Increase to G4 | 0 |
| Lymphocytes:Any Grade Increase | 2 |
| Lymphocytes:Increase to G1 | 0 |
| Lymphocytes:Increase to G2 | 2 |
| Lymphocytes:Increase to G3 | 0 |
| Lymphocytes:Increase to G4 | 0 |
| Total Neutrophils:Any Grade Increase | 7 |
| Total Neutrophils:Increase to G1 | 3 |
| Total Neutrophils:Increase to G2 | 4 |
| Total Neutrophils:Increase to G3 | 0 |
| Total Neutrophils:Increase to G4 | 0 |
| Platelet count:Any Grade Increase | 15 |
| Platelet count:Increase to G1 | 0 |
| Platelet count:Increase to G2 | 8 |
| Platelet count:Increase to G3 | 7 |
| Platelet count:Increase to G4 | 0 |
| White Blood Cell count:Any Grade Increase | 6 |
| White Blood Cell count:Increase to G1 | 3 |
| White Blood Cell count:Increase to G2 | 3 |
| White Blood Cell count:Increase to G3 | 0 |
| White Blood Cell count:Increase to G4 | 0 |
Urinalysis parameters included: urine bilirubin (UB), urine occult blood (UOB), urine glucose (UG), urine ketones (UK), pH, urine protein (UP), urine specific gravity (USG) and urine urobilinogen (UU). The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as 1+, (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Screening, UB, (-), n=45 | 6 |
| Screening, UB, Neg., n=45 | 39 |
| Screening, UOB, 1+, n=45 | 4 |
| Screening, UOB, 2+, n=45 | 1 |
| Screening, UOB, 3+, n=45 | 1 |
| Screening, UOB, (-), n=45 | 6 |
| Screening, UOB, Neg., n=45 | 31 |
| Screening, UOB, trace., n=45 | 2 |
| Screening, UG, (-), n=45 | 7 |
| Screening, UG, 0.5, n=45 | 1 |
| Screening, UG, Neg., n=45 | 37 |
| Screening, UK, (-), n=45 | 7 |
| Screening, UK, Neg., n=45 | 38 |
| Screening, pH, 5, n=45 | 1 |
| Screening, pH, 5.5, n=45 | 9 |
| Screening, pH, 6, n=45 | 9 |
| Screening, pH, 6.5, n=45 | 12 |
| Screening, pH, 7, n=45 | 9 |
| Screening, pH, 7.5, n=45 | 5 |
| Screening, UP, 1+., n=45 | 1 |
| Screening, UP, (-), n=45 | 5 |
| Screening, UP, Neg., n=45 | 35 |
| Screening, UP, trace, n=45 | 4 |
| Screening, UU, 1+, n=45 | 2 |
| Screening, UU, (-), n=45 | 1 |
| Screening, UU, 0.1, n=45 | 5 |
| Screening, UU, 1, n=45 | 6 |
| Screening, UU, 2, n=45 | 4 |
| Screening, UU, trace, n=45 | 19 |
| Screening, UU, normal, n=45 | 8 |
| Screening, USG, 1.005, n=45 | 2 |
| Screening, USG, 1.006, n=45 | 1 |
| Screening, USG, 1.007, n=45 | 2 |
| Screening, USG, 1.008, n=45 | 1 |
| Screening, USG, 1.009, n=45 | 1 |
| Screening, USG, 1.01, n=45 | 3 |
| Screening, USG, 1.011, n=45 | 2 |
| Screening, USG, 1.012, n=45 | 1 |
| Screening, USG, 1.013, n=45 | 1 |
| Screening, USG, 1.014, n=45 | 4 |
| Screening, USG, 1.015, n=45 | 4 |
| Screening, USG, 1.017, n=45 | 2 |
| Screening, USG, 1.018, n=45 | 4 |
| Screening, USG, 1.019, n=45 | 1 |
| Screening, USG, 1.02, n=45 | 8 |
| Screening, USG, 1.021, n=45 | 1 |
| Screening, USG, 1.022, n=45 | 1 |
| Screening, USG, 1.024, n=45 | 1 |
| Screening, USG, 1.025, n=45 | 1 |
| Screening, USG, 1.026, n=45 | 3 |
| Screening, USG, 1.03, n=45 | 1 |
| Baseline, UB, (-), n=45 | 6 |
| Baseline, UB, Neg., n=45 | 39 |
| Baseline, UOB, 1+, n=45 | 1 |
| Baseline, UOB, 2+, n=45 | 1 |
| Baseline, UOB, 3+, n=45 | 2 |
| Baseline, UOB, (-), n=45 | 6 |
| Baseline, UOB, Neg., n=45 | 32 |
| Baseline, UOB, trace., n=45 | 3 |
| Baseline, UG, 2+, n=45 | 1 |
| Baseline, UG, (-), n=45 | 7 |
| Baseline, UG, 0.1, n=45 | 1 |
| Baseline, UG, 0.5, n=45 | 1 |
| Baseline, UG, Neg., n=45 | 35 |
| Baseline, UK, (-), n=45 | 7 |
| Baseline, UK, Neg., n=45 | 38 |
| Baseline, pH, 5, n=45 | 2 |
| Baseline, pH, 5.5, n=45 | 8 |
| Baseline, pH, 6, n=45 | 13 |
| Baseline, pH, 6.5, n=45 | 11 |
| Baseline, pH, 7, n=45 | 7 |
| Baseline, pH, 7.5, n=45 | 3 |
| Baseline, pH, 8, n=45 | 1 |
| Baseline, UP, 1+., n=45 | 1 |
| Baseline, UP, (-), n=45 | 5 |
| Baseline, UP, Neg., n=45 | 36 |
| Baseline, UP, trace, n=45 | 3 |
| Baseline, UU, 1+, n=45 | 7 |
| Baseline, UU, (-), n=45 | 1 |
| Baseline, UU, 0.1, n=45 | 4 |
| Baseline, UU, 1, n=45 | 10 |
| Baseline, UU, 2, n=45 | 1 |
| Baseline, UU, trace, n=45 | 15 |
| Baseline, UU, normal, n=45 | 7 |
| Baseline, USG, 1.003, n=45 | 1 |
| Baseline, USG, 1.005, n=45 | 3 |
| Baseline, USG, 1.006, n=45 | 1 |
| Baseline, USG, 1.007, n=45 | 1 |
| Baseline, USG, 1.009, n=45 | 1 |
| Baseline, USG, 1.01, n=45 | 6 |
| Baseline, USG, 1.011, n=45 | 2 |
| Baseline, USG, 1.012, n=45 | 1 |
| Baseline, USG, 1.013, n=45 | 2 |
| Baseline, USG, 1.014, n=45 | 1 |
| Baseline, USG, 1.015, n=45 | 2 |
| Baseline, USG, 1.016, n=45 | 2 |
| Baseline, USG, 1.017, n=45 | 1 |
| Baseline, USG, 1.018, n=45 | 3 |
| Baseline, USG, 1.019, n=45 | 2 |
| Baseline, USG, 1.02, n=45 | 5 |
| Baseline, USG, 1.021, n=45 | 3 |
| Baseline, USG, 1.022, n=45 | 1 |
| Baseline, USG, 1.023, n=45 | 1 |
| Baseline, USG, 1.025, n=45 | 3 |
| Baseline, USG, 1.028, n=45 | 2 |
| Baseline, USG, 1.03, n=45 | 1 |
| Week 1, UB, Neg, n=1 | 1 |
| Week 1, UOB, Neg, n=1 | 1 |
| Week 1, UG, Neg, n=1 | 1 |
| Week 1, UK, Neg, n=1 | 1 |
| Week 1, pH, 7.5, n=1 | 1 |
| Week 1, UP, trace, n=1 | 1 |
| Week 1, USG, 1.021, n=1 | 1 |
| Week 1, UU, trace, n=1 | 1 |
| Week 2, UB, Neg, n=3 | 3 |
| Week 2, UOB, Neg, n=3 | 3 |
| Week 2, UG, 0.25, n=3 | 1 |
| Week 2, UG, Neg, n=3 | 2 |
| Week 2, UK, Neg, n=3 | 3 |
| Week 2, pH, 6, n=3 | 1 |
| Week 2, pH, 6.5, n=3 | 2 |
| Week 2, UP, Neg, n=3 | 3 |
| Week 2, USG, 1.016, Neg, n=3 | 1 |
| Week 2, USG, 1.019, n=3 | 1 |
| Week 2, USG, 1.02, n=3 | 1 |
| Week 2, UU, 0.1, n=3 | 1 |
| Week 2, UU, trace, n=3 | 1 |
| Week 2, UU, normal, n=3 | 1 |
| Week 3, UB, Neg, n=2 | 2 |
| Week 3, UOB, Neg, n=2 | 2 |
| Week 3, UG, >=1.0, n=2 | 1 |
| Week 3, UG, Neg, n=2 | 1 |
| Week 3, UK, Neg, n=2 | 2 |
| Week 3, pH, 6, n=2 | 1 |
| Week 3, pH, 6.5, n=2 | 1 |
| Week 3, UP, Neg, n=2 | 2 |
| Week 3, USG, 1.015, n=2 | 1 |
| Week 3, USG, 1.02, n=2 | 1 |
| Week 3, UU, 0.1, n=2 | 1 |
| Week 3, UU, 4, n=2 | 1 |
| Week 4, UB, Neg, n=5 | 5 |
| Week 4, UOB, Neg, n=5 | 5 |
| Week 4, UG, >=1.0, n=5 | 1 |
| Week 4, UG, Neg, n=5 | 4 |
| Week 4, UK, Neg, n=5 | 5 |
| Week 4, pH, 5.5, n=5 | 1 |
| Week 4, pH, 6, n=5 | 2 |
| Week 4, pH, 6.5, n=5 | 2 |
| Week 4, UP, Neg, n=5 | 5 |
| Week 4, USG, 1.015, n=5 | 1 |
| Week 4, USG, 1.02, n=5 | 2 |
| Week 4, USG, 1.025, n=5 | 1 |
| Week 4, USG, 1.026, n=5 | 1 |
| Week 4, UU, 1, n=5 | 2 |
| Week 4, UU, 2, n=5 | 1 |
| Week 4, UU, trace, n=5 | 2 |
| Week 7, UB, Neg, n=1 | 1 |
| Week 7, UOB, Neg, n=1 | 1 |
| Week 7, UG, 0.5, n=1 | 1 |
| Week 7, UK, Neg, n=1 | 1 |
| Week 7, pH, 7, n=1 | 1 |
| Week 7, UP, Neg, n=1 | 1 |
| Week 7, USG, 1.02, n=1 | 1 |
| Week 7, UU, 2, n=1 | 1 |
| Week 8, UB, Neg, n=2 | 2 |
| Week 8, UOB, Neg, n=2 | 1 |
| Week 8, UOB, trace, n=2 | 1 |
| Week 8, UG, 0.1 n=2 | 1 |
| Week 8, UG, Neg, n=2 | 1 |
| Week 8, UK, Neg, n=2 | 2 |
| Week 8, pH, 6, n=2 | 2 |
| Week 8, UP, Neg, n=2 | 2 |
| Week 8, USG, 1.023, n=2 | 1 |
| Week 8, USG, 1.025, n=2 | 1 |
| Week 8, UU, 0.1, n=2 | 1 |
| Week 8, UU, trace, n=2 | 1 |
| Withdrawal, UB, Neg, n=4 | 4 |
| Withdrawal, UOB, Neg, n=4 | 4 |
| Withdrawal, UG, 0.5, n=4 | 1 |
| Withdrawal, UG, Neg, n=4 | 3 |
| Withdrawal, UK, Neg, n=4 | 4 |
| Withdrawal, pH, 6, n=4 | 2 |
| Withdrawal, pH, 6.5, n=4 | 1 |
| Withdrawal, pH, 8, n=4 | 1 |
| Withdrawal, UP, Neg, n=4 | 4 |
| Withdrawal, USG, 1.008, n=4 | 1 |
| Withdrawal, USG, 1.01, n=4 | 1 |
| Withdrawal, USG, 1.018, n=4 | 1 |
| Withdrawal, USG, 1.025, n=4 | 1 |
| Withdrawal, UU, 1+, n=4 | 2 |
| Withdrawal, UU, 0.1, n=4 | 1 |
| Withdrawal, UU, 1, n=4 | 1 |
| FU, Week 24, UB, Neg, n=3 | 3 |
| FU Week 24, UOB, 1+, n=3 | 1 |
| FU Week 24, UOB, Neg, n=3 | 2 |
| FU Week 24, UG, Neg, n=3 | 3 |
| FU Week 24, UK, Neg, n=3 | 3 |
| FU Week 24, pH, 5.5, n=3 | 1 |
| FU Week 24, pH, 6, n=3 | 1 |
| FU Week 24, pH, 7, n=3 | 1 |
| FU Week 24, UP, Neg, n=3 | 3 |
| FU Week 24, USG, 1.004, n=3 | 1 |
| FU Week 24, USG, 1.01, n=3 | 1 |
| FU Week 24, USG, 1.02, n=3 | 1 |
| FU Week 24, UU, 0.1, n=3 | 1 |
| FU Week 24, UU, 1, n=3 | 1 |
| FU Week 24, UU, trace, n=3 | 1 |
Urinalysis parameters included: UB, UOB, UG, UK, pH, UP, USG and UU. The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as 1+, (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.
| Participants | Eltrombopag + Antiviral Therapy: Part 2 |
|---|---|
| Antiviral Baseline, UB, (-), n=41 | 5 |
| Antiviral Baseline, UB, Neg., n=41 | 36 |
| Antiviral Baseline, UOB, 1+, n=41 | 1 |
| Antiviral Baseline, UOB, (-), n=41 | 5 |
| Antiviral Baseline, UOB, Neg., n=41 | 33 |
| Antiviral Baseline, UOB, trace., n=41 | 2 |
| Antiviral Baseline, UG, 1+, n=41 | 1 |
| Antiviral Baseline, UG, 2+, n=41 | 1 |
| Antiviral Baseline, UG, (-), n=41 | 5 |
| Antiviral Baseline, UG, 0.25, n=41 | 1 |
| Antiviral Baseline, UG, 0.5, n=41 | 1 |
| Antiviral Baseline, UG, >=1.0, n=41 | 1 |
| Antiviral Baseline, UG, Neg., n=41 | 31 |
| Antiviral Baseline, UK, (-), n=41 | 5 |
| Antiviral Baseline, UK, Neg., n=41 | 35 |
| Antiviral Baseline, UK, trace, n=41 | 1 |
| Antiviral Baseline, pH, 5, n=41 | 1 |
| Antiviral Baseline, pH, 5.5, n=41 | 6 |
| Antiviral Baseline, pH, 6, n=41 | 11 |
| Antiviral Baseline, pH, 6.5, n=41 | 12 |
| Antiviral Baseline, pH, 7, n=41 | 6 |
| Antiviral Baseline, pH, 7.5, n=41 | 4 |
| Antiviral Baseline, pH, 8.5, n=41 | 1 |
| Antiviral Baseline, UP, (-), n=41 | 5 |
| Antiviral Baseline, UP, Neg, n=41 | 34 |
| Antiviral Baseline, UP, trace, n=41 | 2 |
| Antiviral Baseline, USG, 1.005, n=41 | 1 |
| Antiviral Baseline, USG, 1.006, n=41 | 1 |
| Antiviral Baseline, USG, 1.01, n=41 | 3 |
| Antiviral Baseline, USG, 1.011, n=41 | 4 |
| Antiviral Baseline, USG, 1.012, n=41 | 2 |
| Antiviral Baseline, USG, 1.013, n=41 | 2 |
| Antiviral Baseline, USG, 1.014, n=41 | 2 |
| Antiviral Baseline, USG, 1.015, n=41 | 4 |
| Antiviral Baseline, USG, 1.016, n=41 | 3 |
| Antiviral Baseline, USG, 1.017, n=41 | 1 |
| Antiviral Baseline, USG, 1.018, n=41 | 2 |
| Antiviral Baseline, USG, 1.019, n=41 | 1 |
| Antiviral Baseline, USG, 1.02, n=41 | 8 |
| Antiviral Baseline, USG, 1.021, n=41 | 1 |
| Antiviral Baseline, USG, 1.022, n=41 | 1 |
| Antiviral Baseline, USG, 1.023, n=41 | 1 |
| Antiviral Baseline, USG, 1.024, n=41 | 1 |
| Antiviral Baseline, USG, 1.025, n=41 | 1 |
| Antiviral Baseline, USG, 1.026, n=41 | 1 |
| Antiviral Baseline, USG, 1.027, n=41 | 1 |
| Antiviral Baseline, UU, 1+, n=41 | 3 |
| Antiviral Baseline, UU, 0.1, n=41 | 3 |
| Antiviral Baseline, UU, 1, n=41 | 6 |
| Antiviral Baseline, UU, 2, n=41 | 2 |
| Antiviral Baseline, UU, 4, n=41 | 2 |
| Antiviral Baseline, UU, Neg, n=41 | 1 |
| Antiviral Baseline, UU, trace, n=41 | 16 |
| Antiviral Baseline, UU, normal, n=41 | 8 |
| Week 4, UB, (-), n=37 | 6 |
| Week 4, UB, Neg, n=37 | 31 |
| Week 4, UOB, 2+, n=37 | 1 |
| Week 4, UOB, (-), n=37 | 6 |
| Week 4, UOB, Neg, n=37 | 30 |
| Week 4, UG, (-), n=37 | 6 |
| Week 4, UG, 0.1, n=37 | 1 |
| Week 4, UG, Neg, n=37 | 30 |
| Week 4, UK, (-), n=37 | 6 |
| Week 4, UK, Neg, n=37 | 31 |
| Week 4, pH, 5, n=37 | 1 |
| Week 4, pH, 5.5, n=37 | 4 |
| Week 4, pH, 6, n=37 | 9 |
| Week 4, pH, 6.5, n=37 | 12 |
| Week 4, pH, 7, n=37 | 6 |
| Week 4, pH, 7.5, n=37 | 4 |
| Week 4, pH, 8, n=37 | 1 |
| Week 4, UP, (-), n=37 | 4 |
| Week 4, UP, Neg, n=37 | 28 |
| Week 4, UP, trace, n=37 | 5 |
| Week 4, USG, 1.004, n=37 | 1 |
| Week 4, USG, 1.005, n=37 | 3 |
| Week 4, USG, 1.006, n=37 | 3 |
| Week 4, USG, 1.008, n=37 | 1 |
| Week 4, USG, 1.01, n=37 | 2 |
| Week 4, USG, 1.011, n=37 | 2 |
| Week 4, USG, 1.012, n=37 | 1 |
| Week 4, USG, 1.013, n=37 | 2 |
| Week 4, USG, 1.014, n=37 | 1 |
| Week 4, USG, 1.015, n=37 | 4 |
| Week 4, USG, 1.016, n=37 | 1 |
| Week 4, USG, 1.017, n=37 | 2 |
| Week 4, USG, 1.019, n=37 | 1 |
| Week 4, USG, 1.02, n=37 | 6 |
| Week 4, USG, 1.021, n=37 | 2 |
| Week 4, USG, 1.022, n=37 | 2 |
| Week 4, USG, 1.025, n=37 | 3 |
| Week 4, UU, 1+, n=37 | 3 |
| Week 4, UU, 0.1, n=37 | 2 |
| Week 4, UU, 1, n=37 | 7 |
| Week 4, UU, 2, n=37 | 2 |
| Week 4, UU, 4, n=37 | 1 |
| Week 4, UU, 8, n=37 | 1 |
| Week 4, UU, Neg, n=37 | 2 |
| Week 4, UU, trace, n=37 | 15 |
| Week 4, UU, normal, n=37 | 4 |
| Week 8, UB, (-), n=36 | 4 |
| Week 8, UB, 2, n=36 | 1 |
| Week 8, UB, Neg, n=36 | 31 |
| Week 8, UOB, 1+, n=36 | 1 |
| Week 8, UOB, 2+, n=36 | 1 |
| Week 8, UOB, (-), n=36 | 4 |
| Week 8, UOB, Neg, n=36 | 30 |
| Week 8, UG, 1+, n=36 | 1 |
| Week 8, UG, (-), n=36 | 5 |
| Week 8, UG, >=1.0, n=36 | 1 |
| Week 8, UG, Neg, n=36 | 29 |
| Week 8, UK, (-), n=36 | 5 |
| Week 8, UK, Neg, n=36 | 30 |
| Week 8, UK, trace, n=36 | 1 |
| Week 8, pH, 5, n=36 | 1 |
| Week 8, pH, 5.5, n=36 | 4 |
| Week 8, pH, 6, n=36 | 7 |
| Week 8, pH, 6.5, n=36 | 13 |
| Week 8, pH, 7, n=36 | 7 |
| Week 8, pH, 7.5, n=36 | 3 |
| Week 8, pH, 8, n=36 | 1 |
| Week 8, UP, 1+, n=36 | 2 |
| Week 8, UP, (-), n=36 | 2 |
| Week 8, UP, Neg, n=36 | 30 |
| Week 8, UP, trace, n=36 | 2 |
| Week 8, USG, 1.001, n=36 | 1 |
| Week 8, USG, 1.003, n=36 | 1 |
| Week 8, USG, 1.004, n=36 | 1 |
| Week 8, USG, 1.005, n=36 | 2 |
| Week 8, USG, 1.008, n=36 | 4 |
| Week 8, USG, 1.01, n=36 | 3 |
| Week 8, USG, 1.012, n=36 | 1 |
| Week 8, USG, 1.013, n=36 | 3 |
| Week 8, USG, 1.014, n=36 | 1 |
| Week 8, USG, 1.015, n=36 | 2 |
| Week 8, USG, 1.016, n=36 | 3 |
| Week 8, USG, 1.018, n=36 | 3 |
| Week 8, USG, 1.019, n=36 | 1 |
| Week 8, USG, 1.02, n=36 | 2 |
| Week 8, USG, 1.023, n=36 | 2 |
| Week 8, USG, 1.025, n=36 | 4 |
| Week 8, USG, <=1.005, n=36 | 1 |
| Week 8, USG, >=1.030, n=36 | 1 |
| Week 8, UU, 1+, n=36 | 5 |
| Week 8, UU, (-), n=36 | 1 |
| Week 8, UU, 0.1, n=36 | 2 |
| Week 8, UU, 1, n=36 | 7 |
| Week 8, UU, 2, n=36 | 1 |
| Week 8, UU, 4, n=36 | 3 |
| Week 8, UU, Neg, n=36 | 1 |
| Week 8, UU, trace, n=36 | 11 |
| Week 8, UU, normal, n=36 | 5 |
| Week 12, UB, (-), n=36 | 5 |
| Week 12, UB, Neg, n=36 | 31 |
| Week 12, UOB, (-), n=36 | 5 |
| Week 12, UOB, Neg, n=36 | 31 |
| Week 12, UG, (-), n=36 | 5 |
| Week 12, UG, 0.25, n=36 | 1 |
| Week 12, UG, Neg, n=36 | 30 |
| Week 12, UK, (-), n=36 | 5 |
| Week 12, UK, 0, n=36 | 1 |
| Week 12, UK, Neg, n=36 | 30 |
| Week 12, pH, 5, n=36 | 2 |
| Week 12, pH, 5.5, n=36 | 2 |
| Week 12, pH, 6, n=36 | 9 |
| Week 12, pH, 6.5, n=36 | 12 |
| Week 12, pH, 7, n=36 | 7 |
| Week 12, pH, 7.5, n=36 | 4 |
| Week 12, UP, 1+, n=36 | 2 |
| Week 12, UP, (-), n=36 | 3 |
| Week 12, UP, Neg, n=36 | 26 |
| Week 12, UP, trace, n=36 | 5 |
| Week 12, USG, 1.005, n=36 | 2 |
| Week 12, USG, 1.006, n=36 | 3 |
| Week 12, USG, 1.007, n=36 | 1 |
| Week 12, USG, 1.008, n=36 | 1 |
| Week 12, USG, 1.009, n=36 | 1 |
| Week 12, USG, 1.01, n=36 | 1 |
| Week 12, USG, 1.012, n=36 | 2 |
| Week 12, USG, 1.014, n=36 | 2 |
| Week 12, USG, 1.015, n=36 | 7 |
| Week 12, USG, 1.016, n=36 | 1 |
| Week 12, USG, 1.017, n=36 | 1 |
| Week 12, USG, 1.018, n=36 | 2 |
| Week 12, USG, 1.019, n=36 | 2 |
| Week 12, USG, 1.02, n=36 | 5 |
| Week 12, USG, 1.021, n=36 | 2 |
| Week 12, USG, 1.022, n=36 | 2 |
| Week 12, USG, 1.026, n=36 | 1 |
| Week 12, UU, 1+, n=36 | 1 |
| Week 12, UU, 0.1, n=36 | 3 |
| Week 12, UU, 1, n=36 | 4 |
| Week 12, UU, 2, n=36 | 3 |
| Week 12, UU, 4, n=36 | 2 |
| Week 12, UU, Neg, n=36 | 2 |
| Week 12, UU, trace, n=36 | 15 |
| Week 12, UU, normal, n=36 | 6 |
| Week 16, UB, (-), n=36 | 4 |
| Week 16, UB, Neg, n=36 | 32 |
| Week 16, UOB, 1+, n=36 | 2 |
| Week 16, UOB, 2+, n=36 | 2 |
| Week 16, UOB, 3+, n=36 | 1 |
| Week 16, UOB, (-), n=36 | 4 |
| Week 16, UOB, Neg, n=36 | 27 |
| Week 16, UG, (-), n=36 | 4 |
| Week 16, UG, 0.25, n=36 | 1 |
| Week 16, UG, Neg, n=36 | 31 |
| Week 16, UK, (-), n=36 | 4 |
| Week 16, UK, Neg, n=36 | 31 |
| Week 16, UK, trace, n=36 | 1 |
| Week 16, pH, 5, n=36 | 1 |
| Week 16, pH, 5.5, n=36 | 3 |
| Week 16, pH, 6, n=36 | 12 |
| Week 16, pH, 6.5, n=36 | 9 |
| Week 16, pH, 7, n=36 | 8 |
| Week 16, pH, 7.5, n=36 | 3 |
| Week 16, UP, 1+, n=36 | 1 |
| Week 16, UP, (-), n=36 | 3 |
| Week 16, UP, Neg, n=36 | 30 |
| Week 16, UP, trace, n=36 | 2 |
| Week 16, USG, 1.005, n=36 | 2 |
| Week 16, USG, 1.006, n=36 | 1 |
| Week 16, USG, 1.007, n=36 | 1 |
| Week 16, USG, 1.008, n=36 | 2 |
| Week 16, USG, 1.009, n=36 | 1 |
| Week 16, USG, 1.01, n=36 | 3 |
| Week 16, USG, 1.014, n=36 | 1 |
| Week 16, USG, 1.015, n=36 | 7 |
| Week 16, USG, 1.016, n=36 | 2 |
| Week 16, USG, 1.017, n=36 | 1 |
| Week 16, USG, 1.018, n=36 | 2 |
| Week 16, USG, 1.019, n=36 | 4 |
| Week 16, USG, 1.02, n=36 | 3 |
| Week 16, USG, 1.021, n=36 | 1 |
| Week 16, USG, 1.022, n=36 | 2 |
| Week 16, USG, 1.023, n=36 | 1 |
| Week 16, USG, 1.025, n=36 | 1 |
| Week 16, USG, 1.027, n=36 | 1 |
| Week 16, UU, 1+, n=36 | 5 |
| Week 16, UU, 2+, n=36 | 1 |
| Week 16, UU, 0.1, n=36 | 3 |
| Week 16, UU, 1, n=36 | 7 |
| Week 16, UU, 4, n=36 | 2 |
| Week 16, UU, Neg, n=36 | 3 |
| Week 16, UU, trace, n=36 | 11 |
| Week 16, UU, normal, n=36 | 4 |
| Week 20, UB, (-), n=36 | 2 |
| Week 20, UB, Neg, n=36 | 34 |
| Week 20, UOB, 1+, n=36 | 1 |
| Week 20, UOB, (-), n=36 | 2 |
| Week 20, UOB, Neg, n=36 | 33 |
| Week 20, UG, (-), n=36 | 2 |
| Week 20, UG, Neg, n=36 | 33 |
| Week 20, UG, trace, n=36 | 1 |
| Week 20, UK, (-), n=36 | 2 |
| Week 20, UK, Neg, n=36 | 34 |
| Week 20, pH, 5, n=36 | 4 |
| Week 20, pH, 5.5, n=36 | 1 |
| Week 20, pH, 6, n=36 | 10 |
| Week 20, pH, 6.5, n=36 | 8 |
| Week 20, pH, 7, n=36 | 6 |
| Week 20, pH, 7.5, n=36 | 7 |
| Week 20, UP, 1+, n=36 | 2 |
| Week 20, UP, (-), n=36 | 2 |
| Week 20, UP, Neg, n=36 | 30 |
| Week 20, UP, trace, n=36 | 2 |
| Week 20, USG, 1.004, n=36 | 1 |
| Week 20, USG, 1.005, n=36 | 2 |
| Week 20, USG, 1.006, n=36 | 1 |
| Week 20, USG, 1.007, n=36 | 2 |
| Week 20, USG, 1.009, n=36 | 3 |
| Week 20, USG, 1.01, n=36 | 3 |
| Week 20, USG, 1.013, n=36 | 3 |
| Week 20, USG, 1.014, n=36 | 2 |
| Week 20, USG, 1.015, n=36 | 2 |
| Week 20, USG, 1.016, n=36 | 2 |
| Week 20, USG, 1.017, n=36 | 2 |
| Week 20, USG, 1.018, n=36 | 3 |
| Week 20, USG, 1.019, n=36 | 1 |
| Week 20, USG, 1.02, n=36 | 2 |
| Week 20, USG, 1.021, n=36 | 2 |
| Week 20, USG, 1.025, n=36 | 3 |
| Week 20, USG, 1.029, n=36 | 1 |
| Week 20, USG, <=1.005, n=36 | 1 |
| Week 20, UU, 1+, n=36 | 3 |
| Week 20, UU, 2+, n=36 | 1 |
| Week 20, UU, 0.1, n=36 | 2 |
| Week 20, UU, 1, n=36 | 7 |
| Week 20, UU, 4, n=36 | 1 |
| Week 20, UU, 8, n=36 | 2 |
| Week 20, UU, Neg, n=36 | 2 |
| Week 20, UU, trace, n=36 | 13 |
| Week 20, UU, normal, n=36 | 5 |
| Week 24, UB, (-), n=36 | 2 |
| Week 24, UB, Neg, n=36 | 34 |
| Week 24, UOB, 1+, n=36 | 2 |
| Week 24, UOB, 3+, n=36 | 1 |
| Week 24, UOB, (-), n=36 | 2 |
| Week 24, UOB, Neg, n=36 | 30 |
| Week 24, UOB, trace, n=36 | 1 |
| Week 24, UG, (-), n=36 | 2 |
| Week 24, UG, 0.1, n=36 | 1 |
| Week 24, UG, Neg, n=36 | 33 |
| Week 24, UK, (-), n=36 | 2 |
| Week 24, UK, Neg, n=36 | 33 |
| Week 24, UK, trace, n=36 | 1 |
| Week 24, pH, 5, n=36 | 2 |
| Week 24, pH, 5.5, n=36 | 3 |
| Week 24, pH, 6, n=36 | 9 |
| Week 24, pH, 6.5, n=36 | 12 |
| Week 24, pH, 7, n=36 | 6 |
| Week 24, pH, 7.5, n=36 | 3 |
| Week 24, pH, 8.5, n=36 | 1 |
| Week 24, UP, (-), n=36 | 2 |
| Week 24, UP, Neg, n=36 | 28 |
| Week 24, UP, trace, n=36 | 6 |
| Week 24, USG, 1.008, n=36 | 1 |
| Week 24, USG, 1.009, n=36 | 3 |
| Week 24, USG, 1.01, n=36 | 3 |
| Week 24, USG, 1.011, n=36 | 4 |
| Week 24, USG, 1.012, n=36 | 2 |
| Week 24, USG, 1.013, n=36 | 1 |
| Week 24, USG, 1.014, n=36 | 2 |
| Week 24, USG, 1.015, n=36 | 7 |
| Week 24, USG, 1.016, n=36 | 1 |
| Week 24, USG, 1.017, n=36 | 1 |
| Week 24, USG, 1.018, n=36 | 1 |
| Week 24, USG, 1.019, n=36 | 2 |
| Week 24, USG, 1.021, n=36 | 2 |
| Week 24, USG, 1.022, n=36 | 1 |
| Week 24, USG, 1.023, n=36 | 1 |
| Week 24, USG, 1.025, n=36 | 2 |
| Week 24, USG, 1.03, n=36 | 1 |
| Week 24, USG, <=1.005, n=36 | 1 |
| Week 24, UU, 1+, n=36 | 2 |
| Week 24, UU, 3+, n=36 | 1 |
| Week 24, UU, 0.1, n=36 | 2 |
| Week 24, UU, 1, n=36 | 8 |
| Week 24, UU, 2, n=36 | 2 |
| Week 24, UU, 4, n=36 | 1 |
| Week 24, UU, Neg, n=36 | 2 |
| Week 24, UU, trace, n=36 | 13 |
| Week 24, UU, normal, n=36 | 5 |
| Week 28, UB, 1+, n=34 | 1 |
| Week 28, UB, (-), n=34 | 1 |
| Week 28, UB, Neg, n=34 | 32 |
| Week 28, UOB, 1+, n=34 | 1 |
| Week 28, UOB, (-), n=34 | 1 |
| Week 28, UOB, Neg, n=34 | 31 |
| Week 28, UOB, trace, n=34 | 1 |
| Week 28, UG, (-), n=34 | 1 |
| Week 28, UG, 0.5, n=34 | 1 |
| Week 28, UG, Neg, n=34 | 32 |
| Week 28, UK, (-), n=34 | 1 |
| Week 28, UK, Neg, n=34 | 32 |
| Week 28, UK, trace, n=34 | 1 |
| Week 28, pH, 5.5, n=34 | 1 |
| Week 28, pH, 6, n=34 | 12 |
| Week 28, pH, 6.5, n=34 | 11 |
| Week 28, pH, 7, n=34 | 6 |
| Week 28, pH, 7.5, n=34 | 3 |
| Week 28, pH, 8, n=34 | 1 |
| Week 28, UP, 1+, n=34 | 1 |
| Week 28, UP, Neg, n=34 | 27 |
| Week 28, UP, trace, n=34 | 6 |
| Week 28, USG, 1.005, n=34 | 3 |
| Week 28, USG, 1.007, n=34 | 2 |
| Week 28, USG, 1.008, n=34 | 1 |
| Week 28, USG, 1.009, n=34 | 2 |
| Week 28, USG, 1.011, n=34 | 1 |
| Week 28, USG, 1.012, n=34 | 2 |
| Week 28, USG, 1.013, n=34 | 1 |
| Week 28, USG, 1.015, n=34 | 2 |
| Week 28, USG, 1.016, n=34 | 1 |
| Week 28, USG, 1.017, n=34 | 2 |
| Week 28, USG, 1.018, n=34 | 1 |
| Week 28, USG, 1.019, n=34 | 2 |
| Week 28, USG, 1.02, n=34 | 3 |
| Week 28, USG, 1.022, n=34 | 1 |
| Week 28, USG, 1.023, n=34 | 2 |
| Week 28, USG, 1.024, n=34 | 2 |
| Week 28, USG, 1.025, n=34 | 4 |
| Week 28, USG, 1.027, n=34 | 1 |
| Week 28, USG, <=1.005, n=34 | 1 |
| Week 28, UU, 1+, n=34 | 4 |
| Week 28, UU, 0.1, n=34 | 3 |
| Week 28, UU, 1, n=34 | 6 |
| Week 28, UU, 2, n=34 | 2 |
| Week 28, UU, 4, n=34 | 3 |
| Week 28, UU, Neg, n=34 | 1 |
| Week 28, UU, trace, n=34 | 11 |
| Week 28, UU, normal, n=34 | 4 |
| Week 32, UB, (-), n=34 | 1 |
| Week 32, UB, Neg, n=34 | 33 |
| Week 32, UOB, 1+, n=34 | 1 |
| Week 32, UOB, (-), n=34 | 1 |
| Week 32, UOB, Neg, n=34 | 32 |
| Week 32, UG, (-), n=34 | 1 |
| Week 32, UG, Neg, n=34 | 33 |
| Week 32, UK, (-), n=34 | 1 |
| Week 32, UK, Neg, n=34 | 32 |
| Week 32, UK, trace, n=34 | 1 |
| Week 32, pH, 5, n=34 | 1 |
| Week 32, pH, 5.5, n=34 | 2 |
| Week 32, pH, 6, n=34 | 14 |
| Week 32, pH, 6.5, n=34 | 8 |
| Week 32, pH, 7, n=34 | 8 |
| Week 32, pH, 7.5, n=34 | 1 |
| Week 32, UP, (-), n=34 | 1 |
| Week 32, UP, Neg, n=34 | 29 |
| Week 32, UP, trace, n=34 | 4 |
| Week 32, USG, 1.005, n=34 | 2 |
| Week 32, USG, 1.006, n=34 | 1 |
| Week 32, USG, 1.007, n=34 | 1 |
| Week 32, USG, 1.01, n=34 | 4 |
| Week 32, USG, 1.011, n=34 | 1 |
| Week 32, USG, 1.012, n=34 | 1 |
| Week 32, USG, 1.014, n=34 | 1 |
| Week 32, USG, 1.015, n=34 | 4 |
| Week 32, USG, 1.016, n=34 | 3 |
| Week 32, USG, 1.018, n=34 | 2 |
| Week 32, USG, 1.019, n=34 | 1 |
| Week 32, USG, 1.02, n=34 | 6 |
| Week 32, USG, 1.021, n=34 | 3 |
| Week 32, USG, 1.022, n=34 | 3 |
| Week 32, USG, 1.024, n=34 | 1 |
| Week 32, UU, 1+, n=34 | 3 |
| Week 32, UU, 0.1, n=34 | 2 |
| Week 32, UU, 1, n=34 | 7 |
| Week 32, UU, 3, n=34 | 1 |
| Week 32, UU, 4, n=34 | 1 |
| Week 32, UU, 8, n=34 | 1 |
| Week 32, UU, Neg, n=34 | 1 |
| Week 32, UU, trace, n=34 | 12 |
| Week 32, UU, normal, n=34 | 6 |
| Week 36, UB, 1+, n=34 | 1 |
| Week 36, UB, (-), n=34 | 1 |
| Week 36, UB, Neg, n=34 | 32 |
| Week 36, UOB, 2+, n=34 | 2 |
| Week 36, UOB, (-), n=34 | 1 |
| Week 36, UOB, Neg, n=34 | 31 |
| Week 36, UG, (-), n=34 | 1 |
| Week 36, UG, Neg, n=34 | 33 |
| Week 36, UK, 1+, n=34 | 1 |
| Week 36, UK, (-), n=34 | 1 |
| Week 36, UK, Neg, n=34 | 32 |
| Week 36, pH, 5, n=34 | 1 |
| Week 36, pH, 5.5, n=34 | 3 |
| Week 36, pH, 6, n=34 | 9 |
| Week 36, pH, 6.5, n=34 | 7 |
| Week 36, pH, 7, n=34 | 10 |
| Week 36, pH, 7.5, n=34 | 4 |
| Week 36, UP, 1+, n=34 | 1 |
| Week 36, UP, (-), n=34 | 1 |
| Week 36, UP, Neg, n=34 | 30 |
| Week 36, UP, trace, n=34 | 2 |
| Week 36, USG, 1.005, n=34 | 2 |
| Week 36, USG, 1.007, n=34 | 1 |
| Week 36, USG, 1.008, n=34 | 2 |
| Week 36, USG, 1.009, n=34 | 2 |
| Week 36, USG, 1.01, n=34 | 2 |
| Week 36, USG, 1.011, n=34 | 1 |
| Week 36, USG, 1.012, n=34 | 2 |
| Week 36, USG, 1.013, n=34 | 3 |
| Week 36, USG, 1.015, n=34 | 3 |
| Week 36, USG, 1.016, n=34 | 2 |
| Week 36, USG, 1.018, n=34 | 2 |
| Week 36, USG, 1.02, n=34 | 4 |
| Week 36, USG, 1.021, n=34 | 4 |
| Week 36, USG, 1.023, n=34 | 1 |
| Week 36, USG, 1.024, n=34 | 1 |
| Week 36, USG, 1.03, n=34 | 1 |
| Week 36, USG, <=1.005, n=34 | 1 |
| Week 36, UU, 1+, n=34 | 2 |
| Week 36, UU, 0.1, n=34 | 3 |
| Week 36, UU, 1, n=34 | 7 |
| Week 36, UU, 2, n=34 | 1 |
| Week 36, UU, 3, n=34 | 1 |
| Week 36, UU, 4, n=34 | 1 |
| Week 36, UU, Neg, n=34 | 1 |
| Week 36, UU, trace, n=34 | 14 |
| Week 36, UU, normal, n=34 | 4 |
| Week 40, UB, (-), n=33 | 1 |
| Week 40, UB, Neg, n=33 | 32 |
| Week 40, UOB, 2+, n=33 | 1 |
| Week 40, UOB, 3+, n=33 | 1 |
| Week 40, UOB, (-), n=33 | 1 |
| Week 40, UOB, Neg, n=33 | 30 |
| Week 40, UG, (-), n=33 | 1 |
| Week 40, UG, Neg, n=33 | 32 |
| Week 40, UK, (-), n=33 | 1 |
| Week 40, UK, Neg, n=33 | 31 |
| Week 40, UK, trace, n=33 | 1 |
| Week 40, pH, 5.5, n=33 | 4 |
| Week 40, pH, 6, n=33 | 9 |
| Week 40, pH, 6.5, n=33 | 6 |
| Week 40, pH, 7, n=33 | 10 |
| Week 40, pH, 7.5, n=33 | 4 |
| Week 40, UP, (-), n=33 | 1 |
| Week 40, UP, Neg, n=33 | 30 |
| Week 40, UP, trace, n=33 | 2 |
| Week 40, USG, 1.003, n=33 | 1 |
| Week 40, USG, 1.004, n=33 | 1 |
| Week 40, USG, 1.005, n=33 | 2 |
| Week 40, USG, 1.006, n=33 | 1 |
| Week 40, USG, 1.007, n=33 | 2 |
| Week 40, USG, 1.01, n=33 | 2 |
| Week 40, USG, 1.011, n=33 | 1 |
| Week 40, USG, 1.012, n=33 | 3 |
| Week 40, USG, 1.013, n=33 | 3 |
| Week 40, USG, 1.014, n=33 | 1 |
| Week 40, USG, 1.015, n=33 | 1 |
| Week 40, USG, 1.016, n=33 | 3 |
| Week 40, USG, 1.018, n=33 | 1 |
| Week 40, USG, 1.019, n=33 | 2 |
| Week 40, USG, 1.02, n=33 | 4 |
| Week 40, USG, 1.022, n=33 | 1 |
| Week 40, USG, 1.023, n=33 | 2 |
| Week 40, USG, 1.024, n=33 | 1 |
| Week 40, USG, 1.025, n=33 | 1 |
| Week 40, UU, 1+, n=33 | 1 |
| Week 40, UU, 0.1, n=33 | 3 |
| Week 40, UU, 1, n=33 | 6 |
| Week 40, UU, 2, n=33 | 1 |
| Week 40, UU, 3, n=33 | 1 |
| Week 40, UU, 4, n=33 | 1 |
| Week 40, UU, Neg, n=33 | 1 |
| Week 40, UU, trace, n=33 | 13 |
| Week 40, UU, normal, n=33 | 6 |
| Week 44, UB, (-), n=31 | 1 |
| Week 44, UB, Neg, n=31 | 30 |
| Week 44, UOB, 2+, n=31 | 2 |
| Week 44, UOB, (-), n=31 | 1 |
| Week 44, UOB, Neg, n=31 | 28 |
| Week 44, UG, (-), n=31 | 1 |
| Week 44, UG, 0.1, n=31 | 1 |
| Week 44, UG, Neg, n=31 | 29 |
| Week 44, UK, (-), n=31 | 1 |
| Week 44, UK, Neg, n=31 | 29 |
| Week 44, UK, trace, n=31 | 1 |
| Week 44, pH, 5.5, n=31 | 3 |
| Week 44, pH, 6, n=31 | 12 |
| Week 44, pH, 6.5, n=31 | 8 |
| Week 44, pH, 7, n=31 | 6 |
| Week 44, pH, 7.5, n=31 | 2 |
| Week 44, UP, (-), n=31 | 1 |
| Week 44, UP, Neg, n=31 | 27 |
| Week 44, UP, trace, n=31 | 3 |
| Week 44, USG, 1.005, n=31 | 3 |
| Week 44, USG, 1.007, n=31 | 2 |
| Week 44, USG, 1.008, n=31 | 2 |
| Week 44, USG, 1.01, n=31 | 3 |
| Week 44, USG, 1.011, n=31 | 3 |
| Week 44, USG, 1.012, n=31 | 1 |
| Week 44, USG, 1.015, n=31 | 1 |
| Week 44, USG, 1.016, n=31 | 1 |
| Week 44, USG, 1.017, n=31 | 3 |
| Week 44, USG, 1.018, n=31 | 1 |
| Week 44, USG, 1.019, n=31 | 1 |
| Week 44, USG, 1.02, n=31 | 2 |
| Week 44, USG, 1.021, n=31 | 2 |
| Week 44, USG, 1.022, n=31 | 1 |
| Week 44, USG, 1.024, n=31 | 1 |
| Week 44, USG, 1.025, n=31 | 2 |
| Week 44, USG, 1.027, n=31 | 1 |
| Week 44, USG, 1.03, n=31 | 1 |
| Week 44, UU, 1+, n=31 | 3 |
| Week 44, UU, 2+, n=31 | 1 |
| Week 44, UU, 0.1, n=31 | 3 |
| Week 44, UU, 1, n=31 | 7 |
| Week 44, UU, 2, n=31 | 1 |
| Week 44, UU, 4, n=31 | 1 |
| Week 44, UU, Neg, n=31 | 1 |
| Week 44, UU, trace, n=31 | 11 |
| Week 44, UU, normal, n=31 | 3 |
| Week 48, UB, (-), n=31 | 1 |
| Week 48, UB, Neg, n=31 | 30 |
| Week 48, UOB, 3+, n=31 | 1 |
| Week 48, UOB, (-), n=31 | 1 |
| Week 48, UOB, Neg, n=31 | 29 |
| Week 48, UG, (-), n=31 | 1 |
| Week 48, UG, Neg, n=31 | 30 |
| Week 48, UK, (-), n=31 | 1 |
| Week 48, UK, Neg, n=31 | 30 |
| Week 48, pH, 5.5, n=31 | 4 |
| Week 48, pH, 6, n=31 | 6 |
| Week 48, pH, 6.5, n=31 | 14 |
| Week 48, pH, 7, n=31 | 6 |
| Week 48, pH, 8, n=31 | 1 |
| Week 48, UP, (-), n=31 | 1 |
| Week 48, UP, 10, n=31 | 1 |
| Week 48, UP, Neg, n=31 | 26 |
| Week 48, UP, trace, n=31 | 3 |
| Week 48, USG, 1.005, n=31 | 1 |
| Week 48, USG, 1.007, n=31 | 1 |
| Week 48, USG, 1.009, n=31 | 2 |
| Week 48, USG, 1.01, n=31 | 3 |
| Week 48, USG, 1.011, n=31 | 2 |
| Week 48, USG, 1.012, n=31 | 1 |
| Week 48, USG, 1.013, n=31 | 1 |
| Week 48, USG, 1.014, n=31 | 1 |
| Week 48, USG, 1.015, n=31 | 4 |
| Week 48, USG, 1.016, n=31 | 1 |
| Week 48, USG, 1.017, n=31 | 1 |
| Week 48, USG, 1.018, n=31 | 4 |
| Week 48, USG, 1.019, n=31 | 3 |
| Week 48, USG, 1.02, n=31 | 2 |
| Week 48, USG, 1.025, n=31 | 2 |
| Week 48, USG, 1.027, n=31 | 1 |
| Week 48, USG, 1.03, n=31 | 1 |
| Week 48, UU, 1+, n=31 | 2 |
| Week 48, UU, 0.1, n=31 | 4 |
| Week 48, UU, 1, n=31 | 3 |
| Week 48, UU, 2, n=31 | 2 |
| Week 48, UU, 3, n=31 | 1 |
| Week 48, UU, Neg, n=31 | 1 |
| Week 48, UU, trace, n=31 | 14 |
| Week 48, UU, normal, n=31 | 4 |
| Withdrawal, UB, 1+, n=10 | 1 |
| Withdrawal, UB, (-), n=10 | 1 |
| Withdrawal, UB, Neg, n=10 | 8 |
| Withdrawal, UOB, 1+, n=10 | 1 |
| Withdrawal, UOB, (-), n=10 | 2 |
| Withdrawal, UOB, Neg, n=10 | 7 |
| Withdrawal, UG, (-), n=10 | 2 |
| Withdrawal, UG, Neg, n=10 | 8 |
| Withdrawal, UK, (-), n=10 | 2 |
| Withdrawal, UK, Neg, n=10 | 8 |
| Withdrawal, pH, 5, n=10 | 1 |
| Withdrawal, pH, 6, n=10 | 5 |
| Withdrawal, pH, 6.5, n=10 | 2 |
| Withdrawal, pH, 7, n=10 | 2 |
| Withdrawal, UP, Neg, n=10 | 5 |
| Withdrawal, UP, trace, n=10 | 5 |
| Withdrawal, USG, 1.002, n=10 | 1 |
| Withdrawal, USG, 1.009, n=10 | 1 |
| Withdrawal, USG, 1.01, n=10 | 1 |
| Withdrawal, USG, 1.017, n=10 | 1 |
| Withdrawal, USG, 1.018, n=10 | 1 |
| Withdrawal, USG, 1.019, n=10 | 2 |
| Withdrawal, USG, 1.021, n=10 | 1 |
| Withdrawal, USG, 1.023, n=10 | 1 |
| Withdrawal, USG, 1.025, n=10 | 1 |
| Withdrawal, UU, 1+, n=10 | 2 |
| Withdrawal, UU, 1, n=10 | 1 |
| Withdrawal, UU, Neg, n=10 | 1 |
| Withdrawal, UU, trace, n=10 | 3 |
| Withdrawal, UU, normal, n=10 | 3 |
Urinalysis parameters included: UB, UOB, UG, UK, pH, UP, USG and UU. The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as 1+, (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.
| Participants | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Baseline, UB, (-) | 3 |
| FU Baseline, UB, Neg. | 34 |
| FU Baseline, UOB, 1+ | 1 |
| FU Baseline, UOB, 3+ | 1 |
| FU Baseline, UOB, (-) | 3 |
| FU Baseline, UOB, Neg. | 32 |
| FU Baseline, UG, (-) | 3 |
| FU Baseline, UG, Neg | 34 |
| FU Baseline, UK, (-) | 3 |
| FU Baseline, UK, Neg. | 34 |
| FU Baseline, pH, 5 | 1 |
| FU Baseline, pH, 5.5 | 4 |
| FU Baseline, pH, 6 | 10 |
| FU Baseline, pH, 6.5 | 13 |
| FU Baseline, pH, 7 | 8 |
| FU Baseline, pH, 8 | 1 |
| FU Baseline, UP, (-) | 1 |
| FU Baseline, UP, 10 | 1 |
| FU Baseline, UP, Neg | 27 |
| FU Baseline, UP, trace | 8 |
| FU Baseline, USG, 1.002 | 1 |
| FU Baseline, USG, 1.005 | 1 |
| FU Baseline, USG, 1.007 | 1 |
| FU Baseline, USG, 1.009 | 2 |
| FU Baseline, USG, 1.01 | 2 |
| FU Baseline, USG, 1.011 | 2 |
| FU Baseline, USG, 1.012 | 1 |
| FU Baseline, USG, 1.013 | 1 |
| FU Baseline, USG, 1.014 | 1 |
| FU Baseline, USG, 1.015 | 4 |
| FU Baseline, USG, 1.016 | 1 |
| FU Baseline, USG, 1.017 | 2 |
| FU Baseline, USG, 1.018 | 4 |
| FU Baseline, USG, 1.019 | 5 |
| FU Baseline, USG, 1.02 | 2 |
| FU Baseline, USG, 1.021 | 1 |
| FU Baseline, USG, 1.024 | 1 |
| FU Baseline, USG, 1.025 | 3 |
| FU Baseline, USG, 1.027 | 1 |
| FU Baseline, USG, 1.03 | 1 |
| FU Baseline, UU, 1+ | 4 |
| FU Baseline, UU, 0.1 | 3 |
| FU Baseline, UU, 1 | 3 |
| FU Baseline, UU, 2 | 1 |
| FU Baseline, UU, 3 | 1 |
| FU Baseline, UU, Neg | 2 |
| FU Baseline, UU, trace | 17 |
| FU Baseline, UU, normal | 6 |
| FU Week 24, UB, (-) | 2 |
| FU Week 24, UB, Neg. | 35 |
| FU Week 24, UOB, 1+ | 3 |
| FU Week 24, UOB, 3+ | 1 |
| FU Week 24, UOB, (-) | 2 |
| FU Week 24, UOB, Neg. | 26 |
| FU Week 24, UOB, Trace | 5 |
| FU Week 24, UG, 1+ | 1 |
| FU Week 24, UG, (-) | 2 |
| FU Week 24, UG, 0.2 | 1 |
| FUWeek 24, UG, Neg | 33 |
| FU Week 24, UK, (-) | 2 |
| FU Week 24, UK, Neg. | 34 |
| FU Week 24, UK, Trace. | 1 |
| FU Week 24, pH, 5 | 4 |
| FU Week 24, pH, 5.5 | 9 |
| FU Week 24, pH, 6 | 7 |
| FU Week 24, pH, 6.5 | 10 |
| FU Week 24, pH, 7 | 3 |
| FU Week 24, pH, 7.5 | 4 |
| FU Week 24, UP, (-) | 2 |
| FU Week 24, UP, Neg | 32 |
| FU Week 24, UP, Trace | 3 |
| FU Week 24, USG, 1.004 | 1 |
| FU Week 24, USG, 1.005 | 2 |
| FU Week 24, USG, 1.008 | 2 |
| FU Week 24, USG, 1.01 | 5 |
| FU Week 24, USG, 1.011 | 4 |
| FU Week 24, USG, 1.012 | 1 |
| FU Week 24, USG, 1.013 | 2 |
| FU Week 24, USG, 1.015 | 3 |
| FU Week 24, USG, 1.016 | 2 |
| FU Week 24, USG, 1.017 | 4 |
| FU Week 24, USG, 1.018 | 1 |
| FU Week 24, USG, 1.019 | 1 |
| FU Week 24, USG, 1.02 | 2 |
| FU Week 24, USG, 1.021 | 2 |
| FU Week 24, USG, 1.022 | 2 |
| FU Week 24, USG, 1.023 | 1 |
| FU Week 24, USG, 1.024 | 1 |
| FU Week 24, USG, 1.025 | 1 |
| FU Week 24, UU, 0.1 | 5 |
| FU Week 24, UU, 1 | 2 |
| FU Week 24, UU, 4 | 1 |
| FU Week 24, UU, <1.0 | 1 |
| FU Week 24, UU, Neg | 2 |
| FU Week 24, UU, Trace | 18 |
| FUWeek 24, UU, normal | 8 |
The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal= all ECG parameters within accepted normal ranges. Abnormal= ECG findings outside of normal ranges. CS= ECG with a CS abnormality that meets exclusion criteria. NCS= ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Screening, normal, n=45 | 31 |
| Screening, abnormal-NCS, n=45 | 14 |
| Screening, abnormal-CS, n=45 | 0 |
| Antiviral Baseline, normal, n=41 | 26 |
| Antiviral Baseline, abnormal-NCS, n=41 | 14 |
| Antiviral Baseline, abnormal-CS, n=41 | 1 |
| Part 2, week 12, normal, n=36 | 29 |
| Part 2, week 12, abnormal-NCS, n=36 | 7 |
| Part 2, week 12, abnormal-CS, n=36 | 0 |
| Part 2, week 24, normal, n=36 | 29 |
| Part 2, week 24, abnormal-NCS, n=36 | 7 |
| Part 2, week 24, abnormal-CS, n=36 | 0 |
| Part 2, week 36, normal, n=34 | 24 |
| Part 2, week 36, abnormal-NCS, n=34 | 10 |
| Part 2, week 36, abnormal-CS, n=34 | 0 |
| Part 2, week 48, normal, n=31 | 19 |
| Part 2, week 48, abnormal-NCS, n=31 | 12 |
| Part 2, week 48, abnormal-CS, n=31 | 0 |
| Withdrawal, normal, n=14 | 10 |
| Withdrawal, abnormal-NCS, n=14 | 4 |
| Withdrawal, abnormal-CS, n=14 | 0 |
| Worst ECG post Baseline, normal, n=41 | 24 |
| Worst ECG post Baseline, abnormal-NCS, n=41 | 17 |
| Worst ECG post Baseline, abnormal-CS, n=41 | 0 |
The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal= all ECG parameters within accepted normal ranges. Abnormal= ECG findings outside of normal ranges. CS= ECG with a CS abnormality that meets exclusion criteria. NCS= ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.
| Participants | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Baseline, normal | 24 |
| FU Baseline, abnormal-NCS | 13 |
| FU Baseline, abnormal-CS | 0 |
| FU Week 24, normal | 31 |
| FU Week 24, abnormal-NCS | 6 |
| FU Week 24, abnormal-CS | 0 |
Abdominal ultrasound with doppler were taken at Baseline, Week 24, Week 48, withdrawal (WD)/completion (comp). Questions were asked to assess masses suspicious for hepatocellular carcinoma (HCC), ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and other clinically significant findings (OCSF).
| Participants | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Baseline, masses suspicious for HCC detected, n=45 | 0 |
| Baseline, ascites detected, n=45 | 0 |
| Baseline, portal vein thrombosis detected, n=45 | 0 |
| Baseline, measureable spleen breadth, n=45 | 43 |
| Baseline, OCSF, n=45 | 8 |
| Week 24, masses suspicious for HCC detected, n=36 | 1 |
| Week 24, ascites detected, n=36 | 1 |
| Week 24, portal vein thrombosis detected, n=36 | 0 |
| Week 24, measureable spleen breadth, n=36 | 34 |
| Week 24, OCSF, n=36 | 4 |
| Week 48, masses suspicious for HCC detected, n=29 | 0 |
| Week 48, ascites detected, n=29 | 1 |
| Week 48, portal vein thrombosis detected, n=29 | 0 |
| Week 48, measureable spleen breadth, n=29 | 29 |
| Week 48, OCSF, n=29 | 3 |
| WD/comp, masses suspicious for HCC detected, n=37 | 2 |
| WD/comp, ascites detected, n=37 | 2 |
| WD/comp, portal vein thrombosis detected, n=37 | 0 |
| WD/comp, measureable spleen breadth, n=37 | 37 |
| WD/comp, OCSF, n=37 | 6 |
Abdominal ultrasound with doppler were taken during Follow-up Period after Part 2 at FU Week 24. Questions were asked to assess masses suspicious for hepatocellular carcinoma (HCC), ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and other clinically significant findings (OCSF).
| Participants | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Week 24, masses suspicious for HCC detected, | 1 |
| FU Week 24, ascites detected | 1 |
| FU Week 24, portal vein thrombosis detected | 0 |
| FU Week 24, measureable spleen breadth | 36 |
| FU Week 24, OCSF | 4 |
Abdominal ultrasound with doppler were taken at Baseline, Week 24, Week 48, WD/comp. Questions were asked to assess masses suspicious for HCC, ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and OCSF. Spleen measurements included spleen length and spleen width (breadth).
| Centimeters (cm) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Baseline, spleen length, n=45 | 11.5 ± 2.63 |
| Baseline, spleen width (breadth), n=43 | 4.7 ± 1.25 |
| Week 24, spleen length, n=36 | 11.5 ± 2.34 |
| Week 24, spleen width (breadth), n=34 | 4.9 ± 1.21 |
| Week 48, spleen length, n=29 | 11.6 ± 2.27 |
| Week 48, spleen width (breadth), n=29 | 4.5 ± 0.87 |
| WD/comp, spleen length, n=37 | 11.7 ± 2.67 |
| WD/comp, spleen width (breadth), n=37 | 4.5 ± 0.93 |
Abdominal ultrasound with doppler were taken during Follow-up Period after Part 2 at FU Week 24. Questions were asked to assess masses suspicious for HCC, ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and OCSF. Spleen measurements included spleen length and spleen width (breadth).
| Cm | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|
| FU Week 24, spleen length | 11.0 ± 2.61 |
| FU Week 24, spleen width (breadth) | 4.4 ± 1.32 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of study medication until follow-up visit (up to a maximun of 81 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag Dose Escalation: Part 1 | — | 0/45 (0%) | 0/45 (0%) |
| Eltrombopag + Antiviral Therapy: Part 2 | — | 3/41 (7.3%) | 41/41 (100%) |
| Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 | — | 4/41 (9.8%) | 6/41 (14.6%) |
| Event | Eltrombopag Dose Escalation: Part 1 | Eltrombopag + Antiviral Therapy: Part 2 | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/45 | 1/41 | 2/41 |
| Liver injuryHepatobiliary disorders | 0/45 | 1/41 | 0/41 |
| Myeloblast percentage increasedInvestigations | 0/45 | 1/41 | 0/41 |
| ThrombocytosisBlood and lymphatic system disorders | 0/45 | 0/41 | 1/41 |
| Herpes zosterInfections and infestations | 0/45 | 0/41 | 1/41 |
| Trigeminal neuralgiaNervous system disorders | 0/45 | 0/41 | 1/41 |
| Event | Eltrombopag Dose Escalation: Part 1 | Eltrombopag + Antiviral Therapy: Part 2 | Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2 |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/45 | 24/41 | 0/41 |
| AnaemiaBlood and lymphatic system disorders | 0/45 | 22/41 | 0/41 |
| NeutropeniaBlood and lymphatic system disorders | 0/45 | 17/41 | 0/41 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/45 | 16/41 | 0/41 |
| PruritusSkin and subcutaneous tissue disorders | 0/45 | 14/41 | 0/41 |
| RashSkin and subcutaneous tissue disorders | 0/45 | 13/41 | 0/41 |
| HeadacheNervous system disorders | 0/45 | 13/41 | 0/41 |
| StomatitisGastrointestinal disorders | 0/45 | 12/41 | 0/41 |
| MalaiseGeneral disorders | 0/45 | 11/41 | 0/41 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/45 | 9/41 | 0/41 |
| Age, Continuous(Years) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Mean | 57.8 ± 9.65 |
| Sex: Female, Male(Participants) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Female | 30 |
| Male | 15 |
| Race/Ethnicity, Customized(Participants) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Asian - Japanese Heritage | 45 |
| Diagnosis(Participants) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Chronic hepatitis C | 23 |
| Liver cirrosis | 22 |
| HCV genotype(Participants) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| 1a | 0 |
| 1b | 33 |
| 2a | 6 |
| 2b | 5 |
| Others | 1 |
| Child-Pugh Class(Participants) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| A (Score 5 - 6) | 44 |
| B (Score 7 - 9) | 1 |
| C (Score > 9) | 0 |
| Number of Participants with or without previous IFN use(Participants) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Naïve | 24 |
| Experienced | 21 |
| Baseline alanine transaminase (ALT)(IU/L) | Eltrombopag Dose Escalation: Part 1 |
|---|---|
| Mean | 78.2 ± 47.82 |
2 further baseline measures are reported on the registry.
The record gives a start of Jul 2012, a primary completion of May 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag